[Seite 86↓]

6. Literaturverzeichnis

[ACOG`02] ACOG Committee on Gynecologic Practice. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. Gynecol Oncol 2002; 87: 237-239.

[Adam´90] Adam R, Schmidt C, Di Paolo M, Tulusan AH. Long-term follow-up of patients with borderline tumors of the ovaries Gynakol Rundsch. 1990;30 Suppl 1 :48-50.

[AOCTG´00] Advanced Ovarian Cancer Trialists Group Chemotherapy for advanced ovarian cancer. Cochrane Database Syst Rev. 2000;(2): CD001418.

[AJCC`97] Ovary. In: American Joint Committee on Cancer. AJCC Cancer Staging Manual Philadelphia, Pa: Lippincott-Raven Publishers , 5th ed., 1997; 201-206.

[Ak`00] Ak I, Stokkel MP, Pauwels EK. Positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose in oncology. Part II. The clinical value in detecting and staging primary tumours. J Cancer Res Clin Oncol. 2000 Oct; 126(10): 560-574.

[Akahira`01] Akahira JI, Yoshikawa H, Shimizu Y, Tsunematsu R, Hirakawa T, Kuramoto H, Shiromizu K, Kuzuya K, Kamura T, Kikuchi Y, Kodama S, Yamamoto K, Sato S. Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecol Oncol 2001;81: 398-403.

[Alberts`02] Alberts DS, Markman M, Armstrong D, Rothenberg ML, Muggia F, Howell SB . Intraperitoneal therapy for stage III ovarian cancer: a therapy whose time has come ! J Clin Oncol. 2002 Oct 1; 20(19): 3944-3946.

[Alexander`99] Alexander C, Villena-Heinsen CE, Schaefer A, Toth L, Schmidt W, Kirsch CM . Monoclonal antibody MAb-170 for immunoscintigraphic detection of ovarian tumors. Am J Obstet Gynecol. 1999 Sep; 181(3): 513-517.

[Ali-Fehmi`03] Ali-Fehmi R, Che M, Khalifeh I, Malone JM, Morris R, Lawrence WD, Munkarah AR . The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma . Cancer. 2003 Oct 1; 98(7): 1423-1429.

[Allen`99] Allen DG, Coulter J . Survival of patients with epithelial ovarian cancer and the effect of lymphadenectomy in those with stage 3 disease . Aust NZ J Obstet Gynecol 1999;39 : 420-424.

[Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland`02] Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland. Krebs in Deutschland. 3. erweiterte, aktualisierte Ausgabe, Saarbrücken, 2002.

[Armstrong`02] Armstrong DK, Bundy N, Baergen R et al Randomized phase III study of intravenous (IV) paclitaxel and cisplatin versus IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC). A Gynecologic Ongology Group trial (GOG 172). 38th ASCO Annual Meeting 2002; Abstract 803.

[Aunoble`00] Aunoble B, Sanches R, Didier E, Bignon YJ . Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review). Int J Oncol. 2000 Mar; 16(3 ): 567-576.

[Avarez`87] Avarez LD, To A, Boots LR et al. CA 125 as a serum marker for poor prognosis in ovarian malignancies. Gynecol Oncol 1987;26: 284-289.

[Baiocchi`98] Baiocchi G, Grosso G and Di Re E, Systematic pelvic and peraortic lymphadenectomy at second look laparotomy for ovarian cancer . Gynecologic Oncology 1998; 69: 151–156.

[Banks`97] Banks E, Beral V, and Reeves G. The epidemiology of epithelial ovarian cancer: a review. Int J Gynecol Cancer 1997; 7: 425-438.


[Seite innerhalb Literaturhinweis 87↓]

[Barzen`92] Barzen G, Friedmann W, Richter W, Schonegg W, Riess H, Eichstadt H, Lichtenegger W, Felix R. Stellenwert der Radioimmunszintigraphie in der Diagnostik und Verlaufskontrolle des Ovarialkarzinoms im Vergleich zur Computertomographie und "Second Look"-Operation. Nuklearmedizin. 1992; 31: 16-23.

[Bast`83] Bast RCT, Klug TL, St John E et al A randomioimmunoassay using a monoclonal antibody to monitor the course of ovarian cancer. N Engl J Med 1983; 309: 883-887.

[Bell`90] Bell DA, Scully RE. Ovarian serous borderline tumors with stromal microinvasion. A report of 21 cases. Hum Pathol 1990; 21: 397-403.

[Belotti´96] Belotti D, Vergani V, Drudis T, et al The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996; 2: 1843-1849.

[Benedetti-Panici`99] Benedetti-Panici P, Landoni F, Scarabelli C, Winter R, Maggioni A, Ackermann S, Favalli G, Monaghan JM, Grassi R, Greggi S, Amoroso M, Giannarelli D, Torri V, Mangioni C, Hacker N . Systematic aortic and pelvic lymphadenectomy (SAPL) vs resection of any bulky nodes (RBN) only for optimally debulked advanced ovarian cancer (AOC). Preliminary report from an international randomized trial Seventh Biennal Meeting of the International Gynecologic Cancer Society September 26–30, Rome, Italy. Int J Gynecol Cancer 1999; 9(Suppl 1): A 132.

[Berchuk`94] Berchuk A, Kohler MF, Hopkins MP et al Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors. Gynecol. Oncol 1994; 52: 232.

[Berek`99] Berek JS, Bertelsen K, du Bois A, Brady MF, et al Advanced epithelial ovarian cancer: 1998 consensus statements. Annals of Oncology 1999; 10(Suppl. 1): 87–92.

[Berek`01] Berek J, Ehlen T, Gordon A , et al Interim Analysis of a Double Blind Study of Ovarex mAb B43.13 (OV) Versus Placebo (PBO) in Patients with Ovarian Cancer Proc Am Soc Clin Oncol 2001; Abstr. 837.

[Berek`03] Berek JS, Schultes BC, Nicodemus CF. Biologic and immunologic therapies for ovarian cancer. J Clin Oncol 2003; 21(Suppl 10): 168-174.

[Bidwell´99] Bidwell J, Keen L, Gallagher G et al Cytokine gene polymorphism in human disease: On-line databases. Genes Immunity 1999; 1: 3-19.

[Björholm´80] Björkholm E. Granulosa cell tumor: A comparison of survival in patients and matched controls. Am J Obstet Gynecol. 1980; 138: 329-331.

[Blümke`95] Blümke S. Pathologie. Berlin, New York, Walter de Gruyter-Verlag. 1995; 743-748.

[Bolanos´03] Bolanos M, Borrega P, Gonzalez-Beca R. Weekly paclitaxel/carboplatinum (P/CAR) as first-line-chmotherapy in late relapses (LR) of epithelial ovarian cancer (OC). Preliminary results. ASC0 2003, Abstract 870.

[Bolis`95] Bolis G, Colombo N, Pecorelli S et al Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G. Gruppo Interregionale Collaborativo in Ginecologia Oncologica. Ann Oncol. 1995; 6(9): 887-893.

[Bonnefoi`99] Bonnefoi H, A`Hern RP, Fisher C, Macfarlane, Barton D, Blake P, Shepherd JH, Gore ME. Natural history of stage IV epithelial ovarian cancer. J of Clin Oncol. 1999; Issue 3(17): 767.

[Bookman`03-1] Bookman MA, Greer BE, Ozols RF. Optimal therapy of advanced ovarian cancer. Carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5. Int J Gynecol Cancer 2003 Nov-Dec; 13(6): 735-40.

[Bookman`03-2] Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003 Jan 15; 21(2): 283-90.

[Booth`85] Booth M, Beral V. The epidemiology of ovarian cancer in Ovarian Cancer, Hudson CN ed. Oxford University Press, New York 1985; 22-44.


[Seite innerhalb Literaturhinweis 88↓]

[Booth`89] Booth M, Beral V, Smith P. Risk factors for ovarian cancer: a case control study. Brit. J. Cancer 1989 ; (60 ): 592-598.

[Boyd`97] Boyd J, Rubin SC. Hereditary ovarian cancer: Molecular genetics and clinical implications (Review). Gynecol Oncol 1997; 64: 196- 206 .

[Boyd`01] Boyd J. Molecular genetics of hereditary ovarian cancer. In: Rubin S, Sutton G, eds. Ovarian Cancer. Philadelphia: Lippincott, Willliams &Wilkins 2001; 3-17.

[Braun`01] Braun S, Schindlbeck C, Hepp F, Janni W, Kentenich C, Riethmüller G, Pantel K. Occult tumor cells in bone marrow of patients with locoregionelly restricted ovarian cancer predict early distant metastatic relapse. Journal of Clinical Oncology 2001 Jan 15; 19(2): 368-375.

[Bridgewater`99] Bridgewater JA, Nelstrop AE, Rustin GJ, Gore ME, McGuire WP, Hoskins WJ. Comparison of Standard and CA-125 Response Criteria in Patients With Epithelial Ovarian Cancer Treated With Platinum or Paclitaxel. Journal of Clinical Oncology 1999; 17: 501-508.

[Bristow`02] Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta–analysis. J Clin Oncol 2002; 20: 1248-1259.

[Bruchim`01] Bruchim I, Altaras M, Fishman A. Age Contrasts in Clinical Characteristics and Pattern of Care in Patients with Epithelial Ovarian Cancer. Gynecologic Oncology 2001; 86: 27–278.

[Brun`00]Brun JL, Bouzigon E, Saurel J, Chene G, Briex M, Brun G, Hocke C. Prognostic factors for survival of ovarian epithelial cancers: apropos of 287 cases. Gynecol Obstet Fertil 2000; 28(3): 223-31.

[Brun`00] Brun JL, Feyler A, Chene G, Saurel J, Brun G, Hockè C. Long-Term Results and Prognostic Factors in Patients with Epithelial Ovarian Cancer. Gynecologic Oncology 2000; 78: 21-27.

[Burger`94] Burger RA, Grosen EA, Ioli GR, Van Eden ME, Brightbill HD, Gatanaga M, DiSaia PJ, Granger GA, Gatanaga T. Host-tumor interaction in ovarian cancer. Spontaneous release of tumor necrosis factor and interleukin-1 inhibitors by purified cell populations from human ovarian carcinoma in vitro. Gynecol Oncol 1994; 55: 294-303.

[Burghardt`86] Burghardt E, Pickel H, Lahousen M, Stettner H. Pelvic lymphadenectomy in operative treatment of ovarian cancer. American Journal of Obstetrics and Gynecology 1986; 155: 315–319.

[Burghardt`91] Burghardt E, Girardi F, Lahousen M. Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecologic Oncology 1991; 40: 103–106.

[Burke`96] Burke F, Relf M, Negus R, Balkwill F. A cytokine profile of normal and malignant ovary. Cytokine 1996;8:578-85.

[Buy´88] Buy JN, Moss AA, Ghossain MA, Sciot C, Malbec L, Vadrot D, Paniel BJ, Decroix Y. Peritoneal implants from ovarian tumors: CT findings. Radiology 1988; 169: 691-694.

[Cantu´01] Cantu MG, Buda A,Parma G et al Randomized controlled trial of single-agent paclitaxel versus cyclophosphamid, doxorubicin and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol 2001; 19: 3312-22

[Carnino`97] Carnino F, Fuda GC, Ciccone G, Iskra L, Guercio E, Dadone D, Conte PF. Significance of Lymph Node Sampling in Epithelial Carcinoma of the Ovary. Gynecol Oncol 1997; 65: 467-472.

[Cass`01] Cass I, Li AJ, Runowicz CD, Fields AL, Goldberg GL, Leuchter RS, Lagasse LD, Karlan BY. Pattern of lymph node metastases in clinically unilateral stage I invasive epithelial ovarian carcinomas. Gynecol Oncol 2001; 80: 56-61.


[Seite innerhalb Literaturhinweis 89↓]

[Cassileth´84] Cassileth BR, Lusk EJ, Strouse TB, Bodenheimer BJ. Contemporary orthodox methods in cancer medicine. Ann Intern Med. 1984; 101: 105-112.

[Castrilli`97] Castrilli G, Tatone A. IL-1alfa promote growth of neoplastic human cervical cells. Br. J Cancer 1997; 75(6): 855-859.

[Chambers`98] Chambers S, Ivins M, Carcangiu M. Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients. Int J. Cancer (Pred. Oncol.) 1998; 79: 449-454.

[Chekerov´02] Chekerov R, Sehouli J, Könsgen D, Dietrich A, Klaman I, Petschke B, Hoffmann U, Lichtenegger W, Rosenthal A, Dahl E. Expression of DNA topoisomerase II alpha in human ovarian cancer. Journal of Clinical Research and Clinical Oncology 2002; 128(Suppl) Abstract #P:584.

[Chen`87] Chen SS. Survival of ovrian carcinoma with or without lymph node metastasis. Gynecol Oncol 1987 Jul; 27(3): 368-372.

[Chen`92] Chen Y, Wu PC, Lang JH, Ge WJ, Hartge P, Brinton LA. Risk factors for epithelial ovarian cancer in Beijing, China. Int J Epidemiol. 1992; 21: 23-29.

[Chi`01] Chi DS, Liao JB, Leon LF, Venkatraman ES, Hensley ML, Bhaskaran D, Hoskins WJ. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol 2001 Sep; 82(3): 532-7.

[Chi`99] Chi DS, Venkatraman ES, Masson V, Hoskins WJ. The Ability of Preoperative Cerum CA-125 to Predict Optimal Primary Tumor Cytoreduction in Stage III Epithelial Ovarian Carcinoma. Gynecologic Oncology 2000; 77: 227-231.

[Chi`01] Chi D, Liao J, Leon L, Venkatraman E, Hensley M, Bhaskaran D, Hoskins W. Identification of Prognostic Factors in Advanced Epithelial Ovarian Carcinoma. Gynecologic Oncology 2001; 82: 532-537.

[Chiaffarino`01] Chiaffarino F, Pelucchi C, Parazzini F, Negri E, Franceschi S, Talamini R, Conti E, Montella M et La Vecchia C. Reproductive and hormonal factors and ovarian cancer. Annals of Oncology 2001; 12: 337-341.

[Ciaravino`03] Ciaravino et al A study of tolerance and outcome of thalidomide in patients with epithelial ovarian and peritoneal ASCO 2003; Abstract 1859.

[Clark`01] Clark TG, Stewart ME, Altman DG, Gabra H, Smyth JF. A prognostic model for ovarian cancer. Br J Cancer 2001 Sep 28; 85(7): 944-952.

[Clement`95] Clement M, Bischof P, Gruffat C, Ricolleau G, Auvray E, Quillien V, Pacheco C, Torres M, Ferdeghini M. Clinical validation of the new ELSA-CA 125 II assay: report of a European multicentre evaluation. Int J Cancer 1995 Jan 17; 60(2):199-203.

[Clinton`97] Clinton GM, Hua W. Estrogen action in human ovarian cancer. Critical Reviews in Oncology/ Hematology 1997; 25: 1-9.

[Cobleigh`99] Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breastcancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639–2648.

[Cohen´94] Cohen CJ, Jennings TS. Screening for ovarian cancer: the role of noninvasive imaging techniques. Am J Obstet Gynecol. 1994 Apr; 170(4): 1088-94.

[Cole´99] Cole JL, Rinaldi DA, Lormand NA. Phase I trial of topotecan and gemcitabine for patients with previously treated, advanced non-small cell cancer. Proceed. ASCO 1999; 18 Abstract 1930.

[Colombo`00] Colombo N. On behalf of the ICON Collaborators. Randomised trial of Paclitaxel (PTX) and Carboplatin versus a control arm of Carboplatin or CAP (Cyclophosphamide, Doxorubicin & Cisplatin). The third International Collaborative Ovarian Neoplasm Study Group (ICON3). 36th ASCO Annual Meeting. American Society of Clinical Oncology 2000 ; *1500.


[Seite innerhalb Literaturhinweis 90↓]

[Columbo´93] Columbo N, Pitelli MR, Parma F. Cisplatin (P) dose intensità in advanced ovarian cancer )AOC): a randomized study of conventional does (DC) vs dose-intense (DI) cisplatin monochemotherapy. Proc Am Soc Clin Oncol 1993; 12: 255.

[Conte´96] Conte PF, Bruzzone M, Carnino F, Gadducci A, Algeri R, Bellini A, Boccardo F, Brunetti I, Catsafados E, Chiara S, Foglia G, Gallo L, Iskra L, Mammoliti S, Parodi G, Ragni N, Rosso R, Rugiati S, Rubagotti A. High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest. J Clin Oncol. 1996 Feb;14(2): 351-6.

[Cooper`02] Cooper BC, Sood AK, Davis CS, Ritchie JM, Sorosky JI, Anderson B, Buller RE. Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol 2002; 100: 59–64.

[Corps`97] HM, Corps AN, Evans AL, Clark DE, Charnock-Jones DS, Smith SK. Lab Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors. Invest. 1997 Dec; 77(6): 607-14.

[Covens`02] Covens A, Carey M, Bryson P, Verma S, Kee Fung M, Johnston M. Systematic Review of First-Line Chemotherapy for Newly Diagnosed Postoperative Patients with Stage II, III, or IV Epithelial Ovarian Cancer. Gynecologic Oncology 2002; 85: 71-80.

[Cramer`83] Cramer DW, Welch WR, Cassells S, Scully RE. Mumps, menarche, menopause, and ovarian cancer. Am J Obstst Gynecol 1983; 147: 1-6.

[Cramer`89] Cramer DW. Lactase persistence and milk consumption as determinants of ovarian cancer risk. Am J Epidemiol. 1989 Nov; 130(5): 904-10.

[Cramer`99] Cramer DW, Liberman RF, Titus-Ernstoff L et al Genital talc exposure and risk of ovarian cancer . Int J Cancer 1999; 81: 351-6.

[Creasman`98] Creasman W, Shepherd J, Sideri M, Benedet J. Carcinoma of the ovary. J Epidemiol Biostatistics 1998 ; 3: 75-102.

[Cure ´01] Cure H, Bay JO, Plagne R, Chollet P et al High-dose chemotherapy in advanced epithelial ovarian cancer. Bull Cancer 2001 Sep; 88(9): 842-851. Review.

[Curtin´97] Curtin JP, Malik R, Venkatraman ES, Barakat R, Hoskins WJ. Stage IV Ovarian Cancer: Impact of Surgical Debulking. Gynecologic Oncology 1997; 64: 9-12.

[Cutler`75] Cutler SJ, Young JL eds. Thierd National Cancer Survey: Incidence data, Natl Cancer Inst Monogr no.41, DHEW publication (NIH) 1975; 75-787. U.S. government printing office.

[Dabrow´99] Dabrow MB, Gilman PB, Meyer TJ. Combined therapy with topotecan and gemcitabine in patients with inoperable or metastatic NSCLC. Proceed. ASCO 1999; 18 Abstract 1930.

[De Priest`94] De Priest, Varner E, Powell J, Fried A, Puls L, Higgins R, Shenson D, Kryscio R, Hunter JE, Andrews SJ. The efficacy of a sonographic morphology index in identifying ovarian cancer: a multi-institutional investigation. Gynecol Oncol 1994; 55: 174-178.

[De Rosa`95] De Rosa V, di Mangoni S, Brunetti A, Caraco C, Graziano R, Gallo MS, Maffeo A. Computed tomography and second-look surgery in ovarian cancer patients. Correlation, actual role and limitations of CT scan. Eur J Gynecol Oncol 1995; 16: 123-129.

[Degner´95] Degner LF, Kristjanson LJ, Bowman D, et al Information needs and decisional preferences in women with breast cancer. JAMA 1997 May 14; 277(18): 1485-92.

[Dembo`90] Dembo AJ, Davy M, Stenwig AE, Berle EJ, Bush RS, Kjorstad K. Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol. 1990 Feb; 75(2): 263-73.

[Denis´97] Denis MG, Lipart C, Leborgne J, LeHur PA, Galmiche JP, Denis M, Ruud E, Truchaud A, Lustenberger P. Detection of disseminated tumor cells in peripheral blood of colorectal cancer patients. Int J Cancer 1997 Oct 21; 74(5): 540-544.


[Seite innerhalb Literaturhinweis 91↓]

[Denkert`02] Denkert C, Kobel M, Pest S et al Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol. 2002 Mar; 160(3 ): 893-903.

[Denkert`03] Denkert C, Furstenberg A, Daniel PT, Koch I, Kobel M, Weichert W, Siegert A, Hauptmann S. Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference. Oncogene. 2003 Nov 27; 22(54): 8653-61.

[Denkert`04] Denkert C, Weichert W, Pest S, Koch I, Licht D, Kobel M, Reles A, Sehouli J, Dietel M, Hauptmann S . Overexpression of the Embryonic-Lethal Abnormal Vision-like Protein HuR in Ovarian Carcinoma Is a Prognostic Factor and Is Associated with Increased Cyclooxygenase 2 Expression. Cancer Res 2004; 64: 189-195.

[Dent´03] Dent J, Hall GD, Wilkinson N et al Cytogenic alterations in ovarian clear cell carcinoma detect by comparative genomic hybridization. Br. J. Cancer 2003; 88(10): 1578-1583.

[Detmar´00] Detmar SB, Aaronson NK, Wever LD, Muller M, Schornagel JH. How are you feeling? Who wants to know? Patients' and oncologists' preferences for discussing health-related quality-of-life issues. J Clin Oncol. 2000; 15(18): 3295-3301.

[Detmar´01] Detmar SB, Muller MJ, Wever LD, Schornagel JH, Aaronson NK. The patient-physician relationship . Patient-physician communication during outpatient palliative treatment visits: an observational study. JAMA. 2001;14;285(10):1351-1357.

[Di Re`89] Di Re F, Fontanelli R, Raspagliesi F, Di Re E. Pelvic and para-aortic lymphadenectomy in cancer of the ovary. Clinical Obstetrics and Gynecology 1989; 3: 131-142.

[Di Re`96] Di Re F, Baiocchi G, Fontanelli R, Gross G et al Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer: Prognostic significance of node metastasis. Gynecol Oncol 1996 Sep;62(3): 360-365.

[Diel`99] Diel IJ. Metaanalyse zur prognostischen Bedeutung des Tumorzellnachweises im Knochenmark oder. Auf der Suche nach dem unabhängigen Prognosefaktor. Strahlenther.Onkol. 1999; 175: 44-46.

[Dietel`00-1] Dietel M, Hauptmann S. Serous tumors of low malignant potential of the ovary. 1. Diagnostic pathology. Virchows Arch. 2000; 436: 403-412.

[Dietel`00-2] Dietel M, Hauptmann S. Die neue WHO-Klassifikation der Ovarialtumoren:Darstellung und Kommentar Geburtshilfe und Frauenheilkunde 2000; 04: 177-181.

[Dinarello`91] Dinarello CA, Thompson RC. Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol. Today 1991; 12: 404–410.

[DiSaia`02] DiSaia P, Creasman W. Epithelial Ovarian Cancer. Clinical Gynecologic Oncology Mosby 2002; 6th Eds: 289-350.

[DiSaia`03] DiSaia PJ, Bloss JD. New strategies. Treatment of ovarian cancer. Gynecol Oncol. 2003 Aug;90(2 Pt 2): 24-32.

[DiSilvestro`97] DiSilvestro P, Peipert JF, Hogan JW, Granai CO. Prognostic value of clinical variables in ovarian cancer. J Clin Epidemiol 1997 May; 50(5): 501-505.

[Dittrich`03] Dittrich Ch, Sevelda P, Salzer H, Obermair A, Speiser P, Breitenecker G, Schemper M, Kaider A. Austrian Ovarian Cancer Study Group.Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients. 10-year results of a prospective randomised phase III study comparing carboplatin-cisplatin with cyclophosphamide-cisplatin. Eur J Cancer 2003 May; 39(8): 1129-1140.

[Dittrich`96] Dittrich C. Die medikamentöse Therapie des Ovarialkarzinoms. Wien-Med-Wochenschr. 1996; 146: 23-33.


[Seite innerhalb Literaturhinweis 92↓]

[Dixon`01] Dixon DA, Tolley ND, King PH, Nabors LB, McIntyre TM, Zimmerman GA, Prescott SM. Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J Clin Invest. 2001 Dec; 108(11): 1657-65.

[DKG`02] Dt. Krebsgesellschaft. Kurzgefasste Interdisziplinäre Leitlinien. Maligne Ovarialtumoren 2002; 3. Auflage.

[Doll`80] Doll R, Gray R, Hafner B, Peto R. Mortality in relation to smoking: 22 years´observations on female British doctors. Brit Med J. 1980; 280(6219): 967-971.

[Dottino´87] Dottino PR, Goodman HM, Kredentser D et al Clinical trial of etoposide and cisplatin as salvage therapy in advanced ovarian carcinoma. Gynecol Oncol 1987; 27: 350-356.

[Dörffler`94] Dörffler P, Caffier H. Clinical value of CASA versus CA 125 in ovarian cancer. In: Curr Tumor Diagnosis: Applications, clinical relevance, research, trends, cancer of the lung-state and trends in diagnosis and therapy. Klapdor R (ed), Zuckerschwerdt Verlag München, 1994.

[Duntan`03] Duntan et al Phase II study of weekly paclitaxel and weekly carboplatinum in recurrent platinum sensitive ovarian cancer. ASCO 2003; Abstract 1876.

[du Bois`97] du Bois A, Lück HJ, Meier W, Möbus V, Costa S, Richter B, Bauknecht T, Warm M, Schroeder W, Olbricht S, Nitz U, Jackisch C. Carboplatin Plus Paclitaxel as First-Line Chemotherapy in Previously Untreated Advanced Ovarian Cancer. Seminars in Oncology 1997; 24(Suppl 11): 28-33.

[du Bois`99] du Bois A, Lück HJ, Bauknecht T, Meier W, Richter B, Kuhn W, Quaas J, Pfisterer J. First-Line Chemotherapy With Epirubicin, Paclitaxel, and Carboplatin for Advanced Ovarian Cancer: A Phase I/II Study of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group. Journal of Clinical Oncology 1999; 17(Issue 1): 46-51.

[du Bois`00] du Bois A, Lück HJ, Bauknecht Th, Pfisterer J, Meier W. 2nd-line Chemotherapie nach Platin- oder Platin-Paclitaxel-haltiger Primärtherapie beim Ovarialkarzinom: eine systematische Übersicht der publizierten Daten bis 1998. Geburtsh Frauenheilkd 2000; 60: 41–58.

[du Bois`01] du Bois A., Weber B., Pfisterer J. Epirubicin/Paclitaxel/Carboplatin (TEC) Vs. Paclitaxel/Carboplatin (TC) in First-Line Treatment of Ovarian Cancer FIGO Stages IIb ? IV. Interim Results of an AGO?GINECO Intergroup Phase III Trial Meeting. ASCO Annual Meeting 2001; Abstract 805.

[du Bois`03-1] du Bois A, Pfisterer J, Meier W, Wagner U. Improving first-line therapy of advanced ovarian cancer - the AGO Ovarian Cancer Study Group perspective. Int J Gynecol Cancer. 2003 Nov-Dec ;( 13 Suppl)2: 169-171.

[du Bois`03-2] du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S et al A randomized clinical trial of cisplatin / paclitaxel versus carboplatin / paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003; 95: 1320–1329.

[Edmondson`01] Edmondson RJ, Monaghan JM. The epidemiology of ovarian cancer. Int J Gynaecol Cancer 2001; 11(6): 423-429.

[Eiermann´91] Eiermann W, Achterrath W, Lenaz L, Hepp H. Carboplatin/etoposide as first-line chemotherapy in advanced ovarian carcinoma: a pilot study. Cancer Chemother Pharmacol (1991); 27: 389-393.

[Eisenhauer`99] Eisenhauer EA, Gore M, Neijt JP. Ovarian cancer: should we be managing patients with good and bad prognostic factors in the same manner? Ann Oncol 1999; 10(Suppl 1): 9-15.

[Eisenkop`93] Eisenkop SM, Nalick RH, Wang HJ, Teng NN. Peritoneal implant elimination during cytoreductive surgery for ovarian cancer: impact on survival Gynecol Oncol 1993 Nov; 51(2): 224-9.


[Seite innerhalb Literaturhinweis 93↓]

[Eisenkop`98] Eisenkop SM, M.D. Friedman RL, Wang HJ, M.P.H.. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: A prospective study. Gynecologic Oncology 1998; 69: 103-108.

[Eisenkop`00] Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 2000; 88: 144-153.

[Eisenkop`01-1] Eisenkop SM, Spirtos NM. The clinical Signifikance of Occult Macroscopically Positive Retroperitoneal Nodes in Patients with Epithelial Ovarian Cancer. Gynecologic Oncology 2001; 82: 143-149.

[Eisenkop’01-2] Eisenkop SM, Spirtos NM. Procedures Required to Accomplish Complete Cytoreduction of Ovarian Cancer: Is there a Correlation with Biological Aggressiveness and Survival? Gynecologic Oncology 2001; 82: 435-441.

[Elbendare`95] Elbendare AA, Berchuk A, Bast RC. Biology of epithelial ovarian cancer. In: Lawton FG, Neijt JP, Swenerton KD. Epithelial cancer of the ovary. BMJ Publishing Group London 1995; 20-25.

[El-Omar`00] El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M, Fraumeni JF Jr, Rabkin CS, Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 23:404(6776): 398-402.

[Enomoto`03] Enomoto T, Kuragaki C, Yamasaki M, Sugita N et al Is Clear Cell Carcinoma and Mucinous Carcinoma of the Ovary Sensitive to Combination Chemotherapy with Paclitaxel and Carboplatin? 39th ASCO Annual Meeting 2003; Abstract 1797.

[Evans`80] Evans AT, Gaffey TA, MGD, AJF. Clinicopathological review of 118 granulosa and 82 theca cell tumors. Obstet Gynecol 1980; 55: 231-8.

[Fajac`95] Fajac A, Benard J, Lhomme K. C-erB2gene amplification and protein expression in ovarian epithelial tumors: evaluation of their respective prognostic significance by multivariate analysis. Int J Cancer (Pred Oncol.) 1995 ; 65: 146-151.

[Fathalla`71] Fathalla MF. Incessant ovulation – a factor in ovarian neoplasia? Lancet 1971; 2(7716): 163.

[Faw´77] Faw C, Ballentine R, Ballentine L, Van Eys J. Unproved cancer

remedies - A survey of use in pediatric outpatients. JAMA. 1977; 238: 1536-1538.

[Feeley`01] Feeley KM, Wells M. Precursor lesions of ovarian epithelial malignancy. Histopathology 2001 Feb;38(2):87-95.

[Feldman´75] Feldman GB. Lymphatic obstruction in carcinomatous ascites. Cancer Res. 1975 Feb; 35(2): 325-32.

[Ferrandina`02] Ferrandina G, Lauriola L, Zannoni GF, Fagotti A, Fanfani F, Legge F, Maggiano N, Gessi M, Mancuso S, Ranelletti FO, Scambia G. Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol. 2002 Aug; 13(8): 1205-11.

[Fiedman`97] Friedman RL, Eisenkop SM, Wang HJ. Second-look Laparotomy for Ovarian Cancr Provides Reliable Prognostic Information and Improves Survival Gynecologic Oncology 1997; 67: 88-94.

[Fogel´03] Fogel M, Gutwein P, Mechtersheimer S, Riedle S, Stoeck A, Smirnov A, Edler L, Ben-Arie A, Huszar M, Altevogt P. L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. Lancet. 2003 Sep 13; 362(9387): 869-875.

[Folk`95] Folk JJ, Botsford M, Musa AG. Monitoring cancer antigen 125 levels in induction chemotherapy for epithelial ovarian carcinoma and predicting outcome of second-look procedure. Gynecol Oncol 1995; 57: 178-182.


[Seite innerhalb Literaturhinweis 94↓]

[Forman`98] Forman D, Graham DY . Review article: impact of Helicobacter pylori on society-role for a strategy of 'search and eradicate. Aliment Pharmacol Ther. 2004 Feb; 19(Suppl 1): 17.

[Lambrechts`98] Lambrechts AC, van 't Veer LJ, Rodenhuis S. The detection of minimal numbers of contaminating epithelial tumor cells in blood or bone marrow: use, limitations and future of RNA-based methods. Ann Oncol. 1998 Dec; 9(12): 1269-76.

[Forstner`99] Forstner R, Graf A. Diagnostic imaging in staging of gynecologic carcinomas. Radiologe 1999; 39: 610-618.

[Fox`89] Fox H. The concept of borderline malignancy in ovarian tumors: A reappraisal Curr Top Pathol 1989; 78: 111-134.

[Franceschi`91] Franceschi S, La Veccia C, Booth M, Tzonou A, Negri E, Parazzini F et al Pooled analysis of 3 European case-control studies of ovarian cancer: II. Age at menarche and at menopause. Int J Cancer 1991; 49: 57-60.

[Franceschi`94] Franceschi S, La Vecchia C, Negri E et al Fertility drugs and risk of epithelial ovarian cancer in Italy. Hum Reprod 1994; 9: 1673-1675.

[Frank`98] Frank TS, Manley SA, Olopade OI et al Sequence analysis of BRCA 1 and BRCA 2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 1998; 16: 2417-2425.

[Frickhofen´00] Frickhofen D, Bunjes R, Kreienberg et al Final results of the german multicenter phase II-trial of high-dose chemotherapy with stem cell support in advanced ovarian cancer. 36th ASCO Annual Meeting. American Society of Clinical Oncology 2000;*1523. ASCO 2003 ; Abstract *1798.

[Friedländer`81] Friedländer ML, Quinn MA, Fortune D et al The relationship of steroid receptor expression to nuclear DNA distribution and clinicopathological characteristics in epzthelial ovarian tumors. Hum Pathol 1981; 12: 886.

[Friedman`97] Friedman RL, Eisenkop SM, Wang HJ. Second–look laparotomy for ovarian cancer provides reliabla prognostic information and improves survival Gynecol Oncol 1997 Oct; 67(1): 88-94.

[Fujiwaki`99] Fujiwaki R, Hata T, Miyazaki K, Kawamura T and Inada K. Elevation of serum interleukin-1 receptor antagonist levels in women with gynaecological cancers. Br J Obstet Gynaecol 1997; 104(12): 1407-1408.

[Fuks`89] Fuks Z, Newmann CE, Ford C, Jordan JH. Patterns of spread of ovarian carcinoma: relation to therapeutic stratgies. Ovarian Cancer. 1989;39-51.

[Gabriel`00] Gabriel M, Obrebowska A, Spaczynski M. Bone marrow involvement in ovarian cancer determined by immunohistochemical methods. Gynakol Geburtshilfliche Rundsch. 2000; 40(3-4): 140-144.

[Gadducci`98] Gadducci A, Ferdeghini M, Castellani C, Annicchiarico C, Prontera C, Facchini V, Bianchi R, Genazzani AR. Serum macrophage colony-stimulating factor (M-CSF) levels in patients with epithelial ovarian cancer. Gynecol Oncol. 1998 Jul; 70(1): 111-114.

[Ganem´98] Ganem G, Gladieff L, Guastalla JP. Sequential topotecan ans etoposid in pretreated ovarian cancer: a GINECO phase II study. Proceedings of ASCO 1998; *1371.

[Garg`98] Garg P, Kerlikowske K, Subak L, Grady D. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta analysis. Obstet Gynecol 1998; 92: 472-479.

[Garland´95] Garland M, Morris JS, Stampfer MJ, Colditz GA, Spate VL, Baskett CK, Rosner B, Speizer FE, Willett WC, Hunter DJ. Prospective study of toenail selenium levels and cancer among women. J Natl Cancer Inst. 1995 Apr 5;87(7): 497-505.

[Garrisin`89] Garrisin RN, Kaelin L, Galloway RH, Heuser LS. Malignant ascites: Clinical and experimental observations. Ann. Surg. June1989; 203(6): 644-649.


[Seite innerhalb Literaturhinweis 95↓]

[Gastl`93] Gastl G, Plante M, Finstad C, Wong G, Federici MG, Bander NH, Rubin SC. High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer. Br. J. Haematol. 1993; 83: 433-441.

[Geisler`76] Geisler HE, Minor JR, Eastlund ME. The treatment of advanced ovarian carcinoma with high dose, intravenous cyclophosphamide. Gynecol Oncol. 1976 Mar;4(1): 43-52.

[Geisler`96-1] Geisler JP, Miller GA, Lee TH, Harwood RM, Wiemann MC, Geisler HE. Relationship of preoperative serum CA-125 to survival in epithelial ovarian carcinoma. J Reprod Med 1996; 41: 140-142.

[Geisler`96-2] Geisler JP, Wiemann MC, Miller GA et al Estrogen and progesterone receptor status as prognostic indicator in patients with optimally cytoreduced stage IIIc serous cystadenocarcinomaof the ovary. Gynecol. Oncol. 1996; 60: 424-427.

[Gertig´00] Gertig DM, Hunter DJ, Cramer DW, Colditz GA, Speizer FE, Willett WC, Hankinson SE. Prospective study of talc use and ovarian cancer. J Natl Cancer Inst. 2000 Feb 2;92(3): 249-252.

[Gibbs´00] Gibbs D, M Pyle M Allen et al: A phase I dose-finding study of carboplatin (C), paclitaxel (P) and liposomal doxorubicin (LD) in advanced epithelial ovarian carcinoma (EOC). Proc Am Soc Clin Oncol 2000, 19: 1539

[GOG `03] The GynecologicOncology Group Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol. 2003 Jan 15;21(2): 283-290.

[Gore´96] Gore ME, Mainwaring PN, Macfarlane V. A randomized study of high versus standard dose Carboplatin in patients (pts) with advanced ovarian cancer (EOC). Proc Am Soc Clin Oncol 1996;15: 284.

[Gotlieb`92] Gotlieb WH, Abrams JS, Watson JM, Velu TJ, Berek JS, Martinez-Maza-O. Presence of interleukin 10 (IL-10) in the ascites of patients with ovarian and other intra-abdominal cancers. Cytokine. 1992 ;4: 385-390.

[Greggi´01] Greggi S, Salerno MG, D’Agostino G, Ferrandina G, Lorusso D, Manzione L, Mancuso S, Scambia G. Topotecan and gemcitabine in platinum/Paclitaxel-resistant ovarian cancer. Oncology. 2001; 60(1): 19-23.

[Green`97] Green A, Purdie D, Bain C, Siskind V, Russell P, Quinn M, Ward B. Tubal sterilisation, hysterectomy and decreased risk of ovarian cancer. Survey of Women`s Health Study Group. Int J. Cancer 1997; 71: 948-951.

[Griffith`75] Griffith CT. Surgical resection of tumour bulk in the primary treatment of ovarian carcinoma. National Cancer Institute Monograph 1975; 42: 101.

[Gronlund`02] Gronlund B, Hogdall C, Hansen HH, Engelholm SA. Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma. Cancer 2002; 94: 1961-1967.

[Gross`94] Gross TP, Schlesselman JJ. The estimated effect of oral contraceptive use on the culmulative risk of epithelial ovarian cancer. Obstet Gynecol 1994; 83: 419-424.

[Grossi`02] Grossi M, Quinn MA, Thursfield VJ, Francis PA, Rome RM, Planner RS, Gilles GG. Ovarian cancer: patterns of care in Victoria during 1993-1995. Medical Journal Australia 2002; 177 :11-16.

[Grossmann`95] Grossmann M, Hoermann R, Gocze PM, Ott M, Bergers P, Mann K. Measurement of human chorionic gonadotropin-related immunreactivity in serum, ascites and tumour cysts of patients with gynecologic malignancies. European Journal of Clinical Investigation 1995; 25: 867-873.

[Guastalla `01] Guastalla P, Leduc B, Guichard F. et al Cyclophosphamide Dose Intensification with Filgrastim Support in First Line CEP Regimen in Advanced Ovarian Cancer (AOC): a Gineco Phase III Study. ASCO Annual Meeting 2001; Abstract 817.


[Seite innerhalb Literaturhinweis 96↓]

[Grulich`92] Grulich A, Swerdlow A, Head J, Marmot M. Cancer mortality in African and Carribean migrants to England and Wales. Br J Cancer 1992; 66: 905-911.

[Halperin`99] Halperin R, Hadas E, Langer R, Bukovsky I, Schneider D: Peritoneal fluid gonadotropins and ovarian hormones in patients with ovarian cancer . Int J of Gynecol Cancer 1999; 9(6): 502-507.

[Hamm`99] Hamm B, Kubik HR, Fleige B. MR imaging and CT of the female pelvis: radiologic-pathologic correlation. Eur.Radiol. 1999; 9 :3-15.

[Hankinson`92] Hankinson SE, Colditz GA, Hunter DJ, et al A quantitative assessment of oral contraceptive use and risk of ovarian cancer. Obstet Gynecol 1992; 80(4): 708-714.

[Hankinson`95] Hankinson SE, Colditz GA, Hunter DJ et al A prospective study of reproductive factors and risk of epithelial ovarian cancer. Cancer 1995; 76: 284-290.

[Harbeck`94] Harbeck N et al Tumor cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median foll.-up. Br J Cancer 1994; 69: 566–571.

[Hardinham´95] Hardingham JE, Kotasek D, Sage RE, Eaton MC, Pascoe VH, Dobrovic A. Detection of circulating tumor cells in colorectal cancer by immunobead-PCR is a sensitive prognostic marker for relapse of disease. Mol Med. 1995 Nov;1(7): 789-794.

[Harlow`92] Harlow BL, Cramer DW, Bell DA, Welch WR. Perineal exposure to talc and ovarian cancer risk. Obstet Gynecol. 1992 Jul;80(1): 19-26.

[Harrell`85] Harrell FE Jr, Lee KL, Matchar DB, Reichert TA. Regression models for prognostic prediction: advantages, problems, and suggested solutions.` Cancer Treat Rep. 1985 Oct; 69(10): 1071-77.

[Hartge´94] Hartge P, Whittemore AS, Itnyre J and the Collaborative Ovarian Cancer Group. Rates and risks of ovarian cancer in subgroups of white women in the United States. Obstet Gynecol 1994; 84: 760-764.

[Hasholzner´94] Hasholzner U, Baumgartner L, Stieber P et al Significance of the tumor markers CA-125 II, Ca 72-4, CASA and CYFRA 21-1 in ovarian carcinomas. In: R. Klapdor (ed), Current Tumor Diagnosis 1994; 119-122.

[Hauptmann`01] Hauptmann S, Dietel M. Serous tumors of low malignant potential of the ovary-molecular pathology: part 2. Virchows Arch. 438 2001; 539-551.

[Hauser´81] Hauser SP. Krebspatient und Paramedizin. Kontakte, Theorien und Behandlungsweisen. Dissertation, Zürich. 1981.

[Hefler´02] Hefler LA, Ludwig E, Lebrecht A, Zeillinger R, Tong-Cacsire D, Koelbl H, Leodolter S, Tempfer CB. Polymorphisms of the interleukin-1 gene cluster and ovarian cancer. J Soc Gynecol Investig. 2002 Nov-Dec; 9(6 ): 386-90.

[Hefler´03] Hefler LA, Grimm C, Ackermann S, Malur S, Radjabi-Rahat AR, Leodolter S, Beckmann MW, Zeillinger R, Koelbl H, Tempfer CB. An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer. Cancer Res. 2003 Jun 15;63(12 ): 3066-8

[Heintz`85] Heintz APM, Hacker NF, Lagasse LD. Epidemiology and etiologyof ovarian cancer: A review. Obstetrics and Gynecology 1985; 66(1).

[Helzlsouer`95] Helzsouer KJ, Alberg AJ, Gordon GB, et al Serum gonadotropins and steroid hormones in the development of ovarian cancer. JAMA 1995; 274: 1926-1930.

[Helzlsouer`96] Helzlsouer KJ, Alberg AJ, Norkus EP, Morris JS, Hoffman SC, Comstock GW. Prospective study of serum micronutrients and ovarian cancer. J Natl Cancer Inst. 1996 Jan 3; 88(1): 32-37.

[Henderson`71] Henderson WJ, Joslin CAF, Turnbull AC, Griffiths K. Talc and carcinoma of the ovary and cervix . J Obstet Gynaecol Brit Comm 1971; 78: 266-272.

[Henson`88] Henson DE. The histological grading of neoplasms. Arch Pathol Lab Med 1988; 112: 1091.

[Hess`03] Hess V, A`Hern RP, Gore ME. Relative Platinum – Resistance of Mucinous Carcinoma of the Ovary. 39th ASCO Annual Meeting 2003; Abstract 1796.


[Seite innerhalb Literaturhinweis 97↓]

[Hilcoat´85] Hillcoat BL, Campbell JJ, Peperell R et al Phase II trial of VP-16-213 in advanced ovarian carcinoma. Gynecol Oncol 1985; 22: 162-166.

[Hoermann`92] Hoermann R, Gerbes AL, Spoettl G, Jüngst D, Mann K. Immunreactive human chorionic gonadotropine and its free beta-subunits in serum and ascites of patients with malignant tumors. Cancer research 1992 March 15; 52: 1520-1524.

[Holschneider`00] Holschneider CH, Berek JS. Ovarian Cancer: Epidemiology, Biology, and Prognostic Factors. Seminars in Surgical Oncology 2000; 19: 3–10.

[Horn`95] Horn IC, Fricke K, Krugmann J. Histologische Klassifikation und morphologische Prognosefaktoren bei malignen Ovarialtumoren. Zentralblatt für Gynäkologie 1995; 117: 335-345.

[Hoskins`89] Hoskins WJ, Rubin SC, Dulaney E, Chapman D, Almadrones L, Saigo P, Markman M, Hakes T, Reichman B, Jones WB et al Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma. Gynecol Oncol 1989; 34: 365-371.

[Hoskins`93] Hoskins W. Surgical staging and cytoreductive surgery of epithelial ovarian cancer. Cancer 1993; 71: 1534-1540.

[Hoskins`94-1] Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, Ball H, Berek JS. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994 Apr; 170(4 ): 974-980.

[Hoskin´94-2] Hoskins PJKD. Swenerton: Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J. Clin. Oncol. 1994; 12: 60-63.

[Hoskins`94-3] Hoskins WJ. Epithelial Ovarian Carcinoma: Principles of Primary Surgery. Gynecologic Oncology 1994; 55: 91-96.

[Hsieh`04] Hsieh CY, Chen CA, Chou CH, Lai KP, Jeng YM, Kuo ML, Wei LH. Overexpression of Her-2/NEU in Epithelial Ovarian Carcinoma Induces Vascular Endothelial Growth Factor C by Activating NF-kappaB: Implications for Malignant Ascites Formation and Tumor Lymphangiogenesis. J Biomed Sci. 2004 Mar-Apr; 11(2): 249-59.

[Huncharek´03] Huncharek M, Geschwind JF, Kupelnick B. Perineal application of cosmetic talc and risk of invasive epithelial ovarian cancer: a meta-analysis of 11,933 subjects from sixteen observational studies. Anticancer Res. 2003 Mar-Apr; 23(2C): 1955-1960.

[Husain`01] Husain A, Chi DS, Prasad M, Abu-Rustum N, Barakat RR, Brown CL, Poynor EA, Hoskins WJ, Curtin JP. The Role of Laparoscopy in second-Look Evaluations for Ovarian Cancer. Gynecologic Oncology 2001; 80: 44-47.

[ICON-G`87] The International Collaborative Ovarian Neoplasm Group. The reduction in risk of ovarian cancer associated with oral-contraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med 1987; 316(11): 650-655.

[Ikeda`03] Ikeda K, Sakai K, Yamamoto R, Hareyyama H, Tsumura N, Watari H, Shimizus M, Minakami H, Sakuragi N. Multivariate analysis for prognostic significance of histologic subtype, GST-pi, MDR-1, and p53 in stages II-IV ovarian cancer. Int J Gynecol Cancer 2003; 13: 776-784.

[Irwin`91] Irwin KL, Weiss NS, Lee NC, Peterson HB. Tubal sterilization, hysterectomy, and the subsequent occurence of epithelial ovarian cancer. Am J Epidemiol 1991; 134: 362-369.

[Jacobs`90] Jacobs J, Oram J, Fairbanks et al A risk of malignancy index incorporating CA125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynecol 1990; 97: 922-929.

[Jacobs`93] Jacobs I, Davies AP, Bridges J, Stabile I, Fay T, Lower A, Grudzinskas JG, Oram D. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ. 1993 Apr 17; 306(6884): 1030-1034.


[Seite innerhalb Literaturhinweis 98↓]

[Jacobs`96] Jacobs I et Lancaster J. The molecular genetics of sporadic and familial epithelial ovarian cancer . Int J Gynecol Cancer 1996; 6: 337-355.

[Jacobs`98] Jacobs I, van Nagell J., DePriest Jr. PD. Screening for Epithelial Ovarian Cancer; Ovarian Cancer: Controversies in Management; Hrsg.: David M. Gershenson, William P. Mcguire, Medical Division of Pearson Professional Limited 1998;1-15.

[Jacobs`99] Jacobs IJ, Skates SJ, MacDonald N, Menon U, Rosenthal AN, Davies AP, Woolas R, Jeyarajah AR, Sibley K, Lowe DG, Oram DH. Screening for ovarian cancer: a pilot randomised controlled trial Lancet. 1999 Apr 10; 353(9160): 1207-1210.

[Jacobs`04] Jacobs IJ, Menon U. Progress challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics. 2004 Apr; 3(4): 355-366.

[Jänicke`99] Janicke F, Holscher M, Kuhn W, von Hugo R, Pache L, Siewert JR, Graeff H. Radical surgical procedure improves survival time in patients with recurrent ovarian cancer. Cancer. 1992 Oct 15; 70(8): 2129-2136.

[Janni`00] Janni W, Gastroph S, Hepp F, Kentenich C, Rjosk D, Schindlbeck C, Dimpfl T, Sommer H, Braun S. Prognostic significance of an increased number ofmicrometastatic tumor cells in the bone marrow of patients with first recurrence of breast carcinoma. Cancer 2000 May;15;88(10): 2252-2259.

[Jenkins´01] Jenkins V, Fallowfield L, Saul J. Information needs of patients with cancer: results from a large study in UK cancer centres. Br J Cancer 2001; 84: 48-51.

[Jeremias´00] Jeremias J, Ledger WJ, Witkin S. Interleukin 1 receptor antagonist gene polymorphism in women with vulvar vestibulitis Am J Obstet Gynecol 2000; 182(2): 283-285.

[Jeppsson`82] Jeppsson S, Kullander S, Rannevik G. Peripheral and ovarian venous concentrations of gonadal steroids and CEA in woman with ovarian tumors. Acta Obstet Gynecol Scand 1982; 61: 209-212.

[Jeppsson`86] Jeppsson S, Karlsson S, Kullander S. Gonadal steroids, gonadotropins and endometrial histology in postmenopausal women with malignant ovarian tumors. Acta Obstet Gynecol Scand 1986; 65: 207-210.

[Joly`02] Joly F, Mangioni C, Nicoletto M et al A phase 3 study of PSC 833 in combination with paclitaxel and carboplatin (PC-PSC) versus paclitaxel and carboplatin (PC) alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary cancer of the peritoneum. 38th ASCO Annual Meeting 2002; Abstract 806.

[Jungst`92] Jungst D, Xie Y, Gerbes AL Pathophysiology of elevated ascites fluid cholesterol in malignant acites. J Hepatol 1992; 14: 244-248.

[Jurcic`94] Jurcic JG, Scheinberg DA, Houghton AN. Monoclonal antibody therapy of cancer. Cancer Chemother Biol Response Modif. 1994;15: 152-175. Review.

[Kaern`93] Kaern J, Trope CG, Abeler VM . A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982. A review of clinicopathologic features and treatment modalities. Cancer 1993; 71: 1810-1820.

[Kaern´03] Kaern J, Baekelandt M, Trope CG. A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients. Eur J Gynaecol Oncol. 2002; 23(5): 383-389.

[Kant´79] Kant I. Erneuerte Frage: Ob das menschliche Geschlecht im beständigen Fortschreiten zum Besseren sei? (1789) zit. nach: Immanuel Kant: Von den Träumen der Vernunft. Kleine Schriften zur Kunst, Philosophie, Geschichte und Politik, Kiepenheuer, Leipzig/Weimar 1979; 509.

[Kaplan`58] Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc 1958; 53: 457–481.


[Seite innerhalb Literaturhinweis 99↓]

[Kapp´99] Kapp DS, Poschauko J, Stücklschweiger GF, Hackl A, Pickel H, Petru E, Winter R. The prognostic significance of peritoneal seeding and size of postsurgical residual in patients with stage III epithelial ovarian cancer treated with surgery, chemotherapy, and high-dose radiotherapy. Gynecol Oncol 1999 Sept; 74(3).

[Katsumata`01] Katsumata N, Watanabe T, Mukai H et al A phase II trial of weekly paclitaxel/carboplatin as salvage chemotherapy in patients with relapsed ovarian cancer [Abstract]. Proc Am Soc Clin Oncol 2001; 19: 865.

[Kavanagh`03] Kavanagh et al Phase 2 study of tlk286 (gst p1-1 activated glutathione analog) administered weekly in patients with platinum refractory or resistant third-line advanced ovarian cancer. ASCO 2003; Abstract #1816.

[Kaye´96] Kaye SB, Paul J, Cassidy J et al Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group. J Clin Oncol. 1996 Jul;14(7): 2113-2119.

[Kaye´02] Kaye SB, Vasey PA.Docetaxel in ovarian cancer: phase III perspectives and future development. Semin Oncol. 2002 Jun; 29(3 Suppl 12): 22-27.

[Kikkawa`94] Kikkawa F, Kawai M, Mizuno et al Recurrence of epithelial ovarian carcinoma after clinical remission. Gynecol Obstet Invest 1994; 38: 65-69.

[Kim´01] Kim SJ, Ikeda N, Shiba E, Takamura Y, Noguchi S. Detection of breast cancer micrometastases in peripheral blood using immunomagnetic separation and immunocytochemistry. Breast Cancer 2001; 8(1): 63-69.

[Kindermann] Kindermann G, Maassen V, Kuhn W. Laparoscopic management of ovarian tumors subsequently diagnosed as malignant: a survey from 127 German departments of obstetrics and gynecology. J Pelvic Surgery 1996; 2: 245-251.

[Kishi`03] Kishi T, Grass L, Soosaipillai A, Scorilas A, Harbeck N, Schmalfeldt B, Dorn J, Mysliwiec M, Schmitt M, Diamandis EP Human kallikrein 8, a novel biomarker for ovarian carcinoma. Cancer Res. 2003 Jun 1; 63(11): 2771-2774.

[Klemi´90] Klemi PJ, Joensuu H, Salmi T. Prognostic value of flow cytometric DNA content analysis in granulosa cell tumor of the ovary. Cancer. 1990 Mar 1; 65(5): 1189-1193.

[Klip`00] Klip H, Burger CW, Kenemans P, Leeuwen FE. Cancer risk associated with subfertility and ovulation induction: a review. Cancer causes and Control 2000; 11: 319-344.

[Knopf´98] Knopf K, Brown M, Kohn EC. Lack of improvement in survival in patients with relapsed or refractory epithelial ovarian cancer, 1980-1997, ASCO Proceedings 1998;17 Abstract 1385:359 a.

[Kodama`97] Kodama S, Tanaka K, Tokunaga A, Sudo N, Takahashi T, Matsui K. Mulivariate analysis of prognostic factors in patients with ovarian cancer stage I and II. Int J of Gynecol and Obst 1997; 56: 147-153.

[Koensgen`02] Koensgen D, Sehouli J, Katsares I, Oskay G, Stengel D, Porzsolt F, Lichtenegger W. Is quality of life (QOL) a prognostic factor in ovarian cancer. 38th ASCO Annual Meeting 2002; Abstract 2814.

[Kommoss`92] Kommoss F, Pfisterer J, Thome M, Schafer W, Sauerbrei W, Pfleiderer A. Steroid receptors in ovarian carcinoma: Immunohistochemical determination may lead to new aspects. Gynecol Oncol 1992; 47: 317-322.

[Konishi`99] Konishi I, Kuroda H, Mandai M. Review: gonadotropins and development of ovarian cancer. Oncology. 1999 Oct; 57(Suppl 2): 45-48.

[Krebs`86] Krebs HB, Goplerud DR, Kilpatrick SJ, Myers MB, Hunt A. Role of Ca 125 as tumor marker in ovarian carcinoma. Obstet.Gynecol. 1986; 67: 473-477.

[Kreienberg`98] Kreienberg R. Die operative Therapie des Ovarialkarzinoms. Der Onkologe 1998; 4: 1123-1130.

[Kristen´94] Kristen P, Dörffler P, Caffier H. Clinical value of CASA versus CA 125 in ovarian cancer. In: Curr Tumor Diagnosis: Applications, clinical relevance, research, trends, cancer of the lung-state and trends in diagnosis and therapy. Klapdor R (ed), Zuckerschwerdt Verlag München, 1994.


[Seite innerhalb Literaturhinweis 100↓]

[Kristensen`97] Kristensen GB, Trope C. Epithelial ovarian carcinoma. Lancet 1997; 349: 113-117.

[Kristensen`02] Kristensen G, Vergote I, Stuart G et al First line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin (TEC) vs. paclitaxel/carboplatin (TC). Interim results of an NSGO-EORTC-NCIC CTG Gynecologic Cancer Intergroup phase III trial 38th ASCO Annual Meeting 2002; Abstract 805.

[Kristiansen`02] Kristiansen G, Denkert C, Schluns K et al CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival Am J Pathol. 2002 Oct; 161(4): 1215-1221.

[Kubik-Huch`00] Kubik-Huch RA, Dorffler W, von Schulthess GK, Marincek B, Kochli OR, Seifert B, Haller U, Steinert HC. Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma . Eur Radiol. 2000; 10(5): 761-767.

[Kuhn´96] Kuhn W,Schmalfeldt B, Dose J. et al. Die intravenöse oder orale Etoposid-Therapie des Platin-refraktären Ovarialkarzinom-Frührezidivs. Geburtsh. u. Frauenheilk. 1996; 56: 105-110.

[Kuhn`99] Kuhn W, Schmalfeldt B, Reuning U et al Prognostic significance of urokinase (uPA) und ts inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc Br. J. Cancer 1999; 79: 1746-1751.

[Kuhn`01] Kuhn W, du Bois A, Pfisterer J. Operative Therapie des fortgeschrittenen Ovarialkarzinoms. Der Gynäkologe 2001; 34: 1050-1057.

[Kuhn`03] Kuhn W. Therapy for recurrent ovarian cancer. Curr Womens Health Rep. 2003 Feb; 3(1): 33-38.

[Kühnle´87] Kühnle H, Meerpohl H, Get al A phase II study of etoposide in advanced ovarian cancer with primary or secondary resistance to high dose cisplatin containing regimes (Abstr.). Proc ECCO 1987; 4: 214.

[Kurbacher´95] Kurbacher CM, Jager W, Kurbacher JA, Bittl A, Wildt L, Lang N. Influence of human luteinizing hormone on cell growth and CA 125 secretion of primary epithelial ovarian carcinomas in vitro. Tumour Biol. 1995; 16(6): 374-384.

[Kurtz´99] Kurtz AB, Tsimikas JV, Tempany CM et al Diagnosis and staging of ovarian cancer: comparative values of Doppler and conventional US, CT, and MR imaging correlated with surgery and histopathologic analysis--report of the Radiology Diagnostic Oncology Group. Radiology. 1999 Jul; 212(1): 19-27.

[Kupryjanczyk`96] Kupryjanczyk J, Thor AD, Beauchamp R, Poremba C, Scully RE, Yandell DW. Ovarian, peritoneal, and endometrial serous carcinoma: clonal origin of multifocal disease. Mod Pathol. 1996 Mar; 9(3): 166-173.

[Landis´99] Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin. 1999 Jan-Feb; 49(1): 8-31.

[Laufman´99] Laufmann LR, Spiiiridonidis CH, Jones JJ. Gemcitabine and Topotecan – A Phase I Trial Proceed. ASCO 1999; 18 Abstract 837.

[La Vecchia`84] La Vecchia C, Franceschi S, Decarli A et al: Coffee drinking and the risk of epithelial ovarian cancer . Int J Cancer 1984; 33: 559-562.

[La Vecchia`87] La Vecchia C, Decarli A, Negri E et al Dietary factors and the risk of epithelial ovarian cancer. J Nat Cancer Inst 1987; 70: 663-669.

[Lambert`97] Lambert HE, Rustin GJ, Gregory WM, Nelstrop AE. A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study. Ann Oncol. 1997 Apr; 8(4): 327-333.

[Lavin`87] Lavin PT, Knapp RC, Malkasian G et al CA-125 for the monitoring of ovarian carcinoma during primary therapy . Obstet Gynecol Gynecol 1987; 69: 223-227.


[Seite innerhalb Literaturhinweis 101↓]

[Ledermann`03] Ledermann JA. Randomised Trial of Paclitaxel in Combination with Platinum Chemotherapy versus Platinum-based Chemotherapy in the Teatment of Relapsed Ovarian Cancer (ICON 4 / Ovar 2.2). 39th ASCO Annual Meeting 2003; Abstract 1794.

[Lee`92] Lee CM, Changchien CS, Shyu WC, Liaw YF. Serum-ascites Albumin concentration gradient and ascites fibronectin in the diagnosis of malignant ascites. Cancer 1992; 70: 2057-2060.

[Lee`96] Lee L, Schuerer-Maly CC, Lofquist AK, van-Haaften-Day C, Ting JP, White CM, Martin BK, Haskill JS. Taxol-dependent transcriptional activation of IL-8 expression in a subset of human ovarian cancer. Cancer Res. 1996; 56:1303-1308.

[Lengyel`01] Lengyel E, Schmalfeldt, Konik E et al Expression of latent matrix metalloproteinase-9 predicts survival in advanced ovarian cancer. Gynecol Oncol. 2001 Aug; 82(2): 291-298.

[Lichtenegger`98] Lichtenegger W, Sehouli J, Buchmann E, Karajanev C, Weidemann H. Operative results after primary and secondary debulking-operations in advanced ovarian cancer. Journal of Obstet and Gyn Research Dec. 1998; 24(6): 447-451.

[Lichtenegger`01] Lichtenegger W, Sehouli J, Buchmann E, Weidemann H. Das fortgeschrittene Karzinom – Möglichkeiten und Grenzen der operativen Therapie des Ovarialkarzinoms. In Kindermann G, Dimpfl T. Berichtsband des 53. Kongresses der DGGG. Thieme 2001; 94-98.

[Lichtenegger`03] Lichtenegger W, Sehouli J. State of the Art-multimodale Therapie des Ovarialkarzinoms gyn 2003 ;(8): 277-280.

[Lichtenegger`04] Lichtenegger W, Sehouli J, Del Priore G. Anatomy. In: Atlas of Gynecologic Oncology, An -Investigation and Surgery (eds) J Richard Smith, Giuseppe Del Priore, John Curtin, John M Monaghan, in press 2004.

[Liebmann´93] Liebmann JE, Cook JA, Lipschultz C et al Cytotoxic studies of paclitaxel (taxol) in human tumour cell lines. Br J Cancer 1993; 68: 1104-1109.

[Lieberman`00] Lieberman G, Buscombe JR, Hilson AJ, Reid WM, Thakrar D, Maclean AB. Preoperative diagnosis of ovarian carcinoma with a novel monoclonal antibody. Am J Obstet Gynecol. 2000 Sep; 183(3): 534-540.

[Lindner`97] Lindner DJ, Borden EC. Effects of tamoxifen and interferon-beta or the combination on tumor-induced angiogenesis . Int J Cancer. 1997 May 2; 71(3): 456-461.

[Lippman`88] Lippman SM, Alberts DS, Slymen DJ, Weiner S, Aristizabal SA, Luditch A, Davis JR, Surwit EA. Second-look laparotomy in epithelial ovarian carcinoma. Prognostic factors associated with survival duration . Cancer 1988; 61: 2571-2577.

[Liu`03] Liu S, Liu JH, Huang H, Peng XP, Wang YM. Analysis of risk factors for epithelial ovarian cancer recurrence. Ai Zheng . 2003 Nov; 22(11): 1197-1200.

[Lopes´93] Lopes NM, Adams, EG, Pitts TW, et al Cell kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 1993; 32: 235-242.

[Lorenz ´90] Lorenz R, Krestin GP, Schmitz-Rixen T, Arnold G. Bedeutung der Sonographie und Computertomographie für die Diagnostik intraperitonealer Tumorausbreitungen. Fortschr Röntgenstr 1990; 152: 516-522.

[Lorenzen`96] Lorenzen M. The value of MRI in staging gynecologic tumors. Aktuelle. Radiol. 1996; 6: 63-68.

[Lorenzen`98] Lorenzen M, Braun J, Gehrckens A, Nicolas V. Value of MRI, CT and findings in staging of gynecologic malignancies. Aktuelle.Radiol. 1998;8:266-272.

[Lorusso`03] Lorusso PM. Phase I studies of ZD1839 in patients with common solid tumors. Semin Oncol. 2003 Feb; 30(1 Suppl 1): 21-29.

[Low`99] Low RN, Saleh F, Song SY et al Treated ovarian cancer: comparison of MR imaging with serum CA-125 level and physical examination--a longitudinal study. Radiology 1999; 211: 519-528.


[Seite innerhalb Literaturhinweis 102↓]

[Lück`03] Lück H.J, Kommoss F, Riener E et al HER2- expression in advanced ovarian cancer: A prognostic and predictive marker? European Journal of Cancer Supplements 2003 Sep; 1(5): 16.

[Lutz`01] Lutz L, Kuhn W, Späthe K. Chemotherapie . In Kuhn: Manual maligne Ovarialtumoren Empfehlungen zur Diagnostik, Therapie und Nachsorge. Tumorzentrum München 2001; 77 : 35.

[Lynch`96] Lynch HT. Smyrk T . Hereditäres nonpolyposis colorectal cancer (Lynch syndrome). An updated review . Cancer 1996; 78: 1149-1167.

[Maggioni`99] Maggioni A, Maneshi F, Maggioni C et al Randomized trial of lymphadenektomie (LY) vs, sampling (SA) or resection of bulky nodes (RBN) as primary surgical procedure in early epithelial ovarian cancer . International journal of Gynecological cancer 1999; 9 : 43.

[Mählck`88] Mählck CG, Bäckström T, Kjellgren O. Plasma Level of Estradiol in Patients with Ovarian Malignant Tumors. Gynecologic Oncology 1988;30: 313-320.

[Mählck`90] Mählck CG, M.D, D. Ph,Grankvist K, Kjellgren O et al Human chorionic gonadotropin, follicle-stimulating hormone, and luteinizing hormone in patients with epithelial ovarian carcinoma. Gynecologic Oncology 1990;36: 219-225.

[Makar`95] Makar A, Baekelandt M, Tropè CO, Kristensen GB. The prognostic Significance of Residual Disease, FIGO Substage, Tumor Histology, and Grade in Patients with FIGO Stage III Ovarian Cancer. Gynecol Oncology 1995 Feb;56(2): 175-180.

[Makhija`99] Makhija S, Sabbatini P, Barakat RR. Intraperitoneal chemotherapy strategies in the treatment of epithelial ovarian carcinoma. Curr Opin Obstet Gynecol. 1999 Feb;11(1): 23-27.

[Malkasian`84] Malkasian GD, Melton LJ, O`Brien PC, Greene MH. Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary. Am J Obstet Gynecol 1984;149: 274–284.

[Manenti`03] Manenti L, Paganoni P, Floriani I, Landoni F, Torri V, Buda A, Taraboletti G, Labianca R, Belotti D, Giavazzi R. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. Eur J Cancer. 2003 Sep;39(13): 1948-1956.

[Mangioni`76] Mangioni C, Bolis G, Natale N, Morasca L. Continuous low-dose cyclophosphamide (NSC-26271) therapy in advanced ovarian cancer. Eur J Cancer. 1976 May;12(5): 353-356.

[Mantovani`95] Mantovani G, Maccio A, Versace R, Pisano M, Lai P, Esu S, Ghiani M, Dessi D, Turnu E, Santona MC. Tumor-associated lymphocytes (TAL) are competent to produce higher levels of cytokines in neoplastic pleural and peritoneal effusions than those found in sera and are able to release into culture higher levels of IL-2 and IL-6 than those released by PBMC . J. Mol. Med. 1995;73: 409-416.

[Marchbank`00] Marchbank PA, Wilson H, Bastos E, Cramer DW, Schildkraut JM, Peterson HB. Cigarette smoking and epithelial ovarian cancer by histologic type. Obstetrics Gynecology 2000 Feb;95(2): 255-260.

[Marchetti`02] Marchetti M, Zambon A, Lamaina V, Spadaro M, Marchioro S. Ultrasound as a possible screening method in ovarian cancer. Eur J Gynaecol Oncol 2002;23: 123-126.

[Markman`92] Markman M, Reichman B, Hakes T, Lewis JL, Jones W, Rubin S, Barakat R, Curtin J, Almadrones L, Hoskins W. Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer . J Clin Oncol 1992;10: 1479-1484.

[Markman`93] Markman M, Lewis JL, Saigo P, Hakes T, Rubin S, Jones W, Reichman B, Curtin J, Barakat R, Almadrones L, Morrissey T, Hoskins W. Impact of Age on Survival of Patients with Ovarian Cancer. Gynecologic Oncology 1993;49: 236-239.


[Seite innerhalb Literaturhinweis 103↓]

[Markman`00] Markman M, Bookman MA. Second-line treatment of ovarian cancer. Oncologist. 2000;5(1): 26-35.

[Markman`01] Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, Wadler S, Sickel J. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001 Feb 15;19(4): 1001-1007.

[Markman`03] Markman M, Markman JR, Zanotti KM, et al Duration of response to second-line platinum-based chemotherapy for ovarian cancer: Implications for patient management and clinical trial design . Proc Am Soc Clin Oncol 2003;22 Abstract 1795: 447.

[Markowska`00] Markowska J, Wilkoszarska J, Emerich J, Deniak J, Popiela A, Panszczak M et al Factors influencing period of time between negative second look laparotomy and ovarian carcinoma recurrence. Multicenter study in Poland. Eur-J-Gynaecol-Oncol. 2000;21(2): 164-167.

[Marra`95] Marra G, Boland C. Hereditary nonpolyposis colorectal cancer. J Natl Cancer Inst 1995;87:1114-1125.

[Marth`02] Marth C, Kisic J, Kaern J, Trope C, Fodstad O. Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian carcinoma do not predict prognosis. Cancer. 2002 Feb 1;94(3): 707-712.

[Massi`96] Massi D, Susini T, Savino L, Boddi V, Amunni G, Colafranceschi M. Epithelial ovarian tumors in the reproductive age group. Cancer 1996;77: 1131-1136.

[Matias-Guiu`98] Matias-Guiu X, Prat J. Molecular pathology of ovarian carcinomas. Virchows Arch. 1998 Aug;433(2): 103-111.

[Mayr`00] Mayr D, Diebold J. Grading of ovarian carcinomas. Int J Gynecol Pathol. 2000 Oct;19(4): 348-53.

[McGovan`73] McGovan L, Davis RH, Bunnag B. The biochemical diagnosis of ovarian cancer. Am J Obstet Gynecol 1973 July 15;116(6).

[McGuckin`93] McGuckin MA, Ramm LE, Joy GJ, et al Circulating tumor-associated mucin concentrations, determined by the CASA assay, in healthy women. Clinica Chimica Acta 1993;214: 139-151.

[McGuire´95] McGuire WP, Hoskins WJ, Brady MF, Homesley HD, Creasman WT, Berman ML, Ball H, Berek JS, Woodward J. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer. A Gynecologic Oncology Group study. J Clin Oncol. 1995 Jul;13(7): 1589-1599.

[McGuire`96] McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334: 1–6.

[McGuire`97] McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: a Gynecologig Oncology Group study. Semin Oncol 1997;24(Suppl. 2): 13-16.

[McGuire`02] McGuire V, Jesser AJ, Whittemore AS. Survival among U.S. Women with Invasive Epithelial Ovarian Cancer. Gynecol Oncol 2002;84: 399-403.

[Meerpohl`02] Meerpohl HG. Primäre Therapie des Ovarialkarzinoms . In Sehouli J, Lichtenegger W. Chemotherapien in der Gynäkologischen Onkolgie. Akademos 2002;97-107.

[Meerpohl`85] Meerpohl HG. Prognostic factors of ovarian cancer. Onkologie 1985;8(5): 296-304.


[Seite innerhalb Literaturhinweis 104↓]

[Meerpohl´97-1] Meerpohl HG, Sauerbrei W, Kuhnle H, Schumacher M, Pfleiderer A. Randomized study comparing carboplatin/cyclophosphamide and cisplatin/cyclophosphamide as first-line treatment in patients with stage III/IV epithelial ovarian cancer and small volume disease. German Ovarian Cancer Study Group (GOCA). Gynecol Oncol . 1997 Jul;66(1): 75-84.

[Meerpohl´97-2] Meerpohl HG, du Bois A, Luck HJ, Kuhnle H, Mobus V, Kreienberg R, Bauknecht T, Kochli O, Bochtler H, Diergarten K . Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer: a phase I trial Semin Oncol . 1997 Feb;24(1 Suppl 2): S2-17-S2-22.

[Meerpohl`97-3] Meerpohl HG. Die Second-look-Operation beim Ovarialkarzinom. Ist eine Neubewertung erforderlich? Der Gynäkologe 1997; 30: 118-125.

[Meier`97] Meier W. Sinnvoller Einsatz der Tumormarker beim Ovarialkarzinom. Der Gynäkologe 1997;30:133-140.

[Meier`03] Meier W et al Topotecan vs treosulfan in recurrent ovarian cancer (oc) after initial therapy with platinum and paclitaxel. A prospective randomized phase III study. ASCO 2003;#1810.

[Meigs`34] Meigs JV. Tumors of the female pelvic organs. Mc Millan New York 1934.

[Menon`00] Menon U, Talaat A, Rosenthal AN, Macdonald ND, Jeyerajah AR, Skates SJ, Sibley K, Oram DH, Jacobs IJ. Performance of ultrasound as a second line test to serum CA 125 in ovarian cancer screening. BJOG 2000;107: 165-169.

[Mettlin´90] Mettlin CJ, Piver MS. A case-control study of milk-drinking and ovarian cancer risk. Am J Epidemiol . 1990 Nov;132(5): 871-876.

[Miller`92] Miller DS, Spirtos NM, Ballon SC, Cox RS, Soriero OM, Teng NN. Critical reassessment of second-look exploratory laparotomy for epithelial ovarian carcinoma. Minimal diagnostic and therapeutic value in patients with persistent cancer. Cancer 1992;69: 502-510.

[Miller´97] Miller B.E., Barron B.A., Wan J.Y. et al Prognostic factors in adult granulosa cell tumor of the ovary. Cancer. 1997;79: 1951-1955.

[Minguillon`93] Minguillon C, Schönborn I, Reles A, Bartel U, Lichtenegger W. EGF-R and PCNA expression in ovarian carcinomas--correlation with classic prognostic factors. Gen. Diagn. Pathol. 1996;141: 197-201.

[Möbus`01] Mobus V, Pfaff PN, Volm T et al Long time therapy with topotecan in patients with recurrence of ovarian carcinoma. Anticancer Res. 2001 Sep-Oct;21(5): 3551-3556.

[Mooney´87] Mooney K. Unproved cancer treatment usage in cancer patients who received conventional therapy (meeting abstract). Oncology Nursing Forum. 1987;14: 112.

[Moradi`93] Moradi MM, Carson LF, Weinber, B, Haney AF, Twiggs LB, Ramakrishnan S. Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer. Cancer 1993;72 : 2433-2440.

[Morris`03] Morris et al Topotecan weekly bolus chemotherapy for potentially chemosensitive relapsed ovarian cancer and peritoneal cancer – an update. ASCO 2003;Abstract #1846.

[Mosgaard`97] Mosgaard BJ, Lidegaard O, Kjaer SK, Schou G, Andersen AN. Infertility, fertility drugs, and invasive ovarian cancer: a case-control study. Fertil Steril 1997;67: 1005-1012.

[Moss`02] Moss C, Kaye SB. Ovarian cancer: progress and continuing controversies in management. Eur J Cancer. 2002 Sep;38(13): 1701-1707.

[Münstedt´96] Münstedt K, Kirsch K, Milch W, Sachse S, Vahrson H.

Unconventional cancer therapy-survey of patients with gynaecological malignancy. Arch Gynecol Obstet. 1996;258: 81-88.


[Seite innerhalb Literaturhinweis 105↓]

[Muggia`00] Muggia FM, Braly P, Brady MF. Phase III randomized study of cisplatin versus paclitaxel in patients with suboptimal stage III or IV ovarian cancer. A gynecologic Oncology Group Study. JCO 2000;18(1): 106-115.

[Muggia`03] Muggia FM. Sequential single agents as first-line chemotherapy for ovarian cancer: a strategy derived from the results of GOG-132. Int J Gynecol Cancer. 2003 Nov-Dec; 13(Suppl 2): 156-162.

[Mujoo´03] Mujoo K, Watanabe M, Nakamura J, Khokhar AR, Siddik ZH. Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents . J Cancer Res Clin Oncol. 2003 Dec; 129(12): 709-718. Epub 2003 Sep 26.

[Munnel`68] Munnel EW. The changing prognosis and treatment in cancer of the ovary. Am J Obstet Gynecol 1968; 100: 790.

[Nakayama`03] Nakayama K, Takebayashi Y, Nakayama S, Hata K, Fujiwaki R, Fukumoto M, Miyazaki K. Prognostic value of overexpression of p53 in human ovarian carcinoma patients receiving cisplatin. Cancer Lett. 2003 Mar 31;192(2): 227-235.

[Narod`01] Narod SA, Sun P, Ghadirian P, Lynch H, Isaacs C, Garber J, Weber B, Karlan B, Fishman D, Rosen B, Tung N, Neuhausen S. Tubal ligation and risk of ovarian cancer in carriers of BRCA 1 or BRCA 2 mutations: a case-control study. Lancet 2001; 357: 1467-1470.

[Narod`98] Narod SA, Risch H, Moslehi R et al Oral contrazeptives and the risk of hereditary ovarian cancer. N Engl J Med 1998; 13: 424-428.

[Ngan´89] Ngan HY, Choo YC, Cheung M, Wong LC, Ma HK, Collins R, Fung C, Ng CS, Wong V, Ho HC et al A randomized study of high-dose versus low-dose cis-platinum combined with cyclophosphamide in the treatment of advanced ovarian cancer. Hong Kong Ovarian Carcinoma Study Group. Chemotherapy. 1989; 35(3): 221-227.

[Negri`91] Negri E, Franceschi S, Tzonou A, et al Pooled analysis of 3 European case-control studies. I. Reproductive factors and risk of epithelial ovarian cancer . Int J Cancer 1991;49: 50-56.

[Nguyen`93] Nguyen HN, Averette HE, Hoskins W, Sevin BU, Penalver M, Steren A. National survey of ovarian carcinoma.VI.Critical assessment of current International Federation of Gynecology and Obstetrics staging system. Cancer 1993;72: 3007-3011.

[NIH`94] NIH: National Institutes of Health Consensus Development Conference Statement. Ovarian Cancer: Screening, Treatment, and Follow-up. Gynecologic Oncology 1994;55: 4-12.

[O´Byrne`02] O'Byrne KJ, Bliss P, Graham DJ et al A phase III study of Doxil/Caelyx versus paclitaxel in platinum-treated, taxan-naive relapsed ovarian cancer. ASCO 2002;Abstract #808.

[Obermair`98] Obermair A, Tempfer C, Hefler L, Preyer O, Kaider A, Zeillinger R, Leodolter S, Kainz C. Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with suspected ovarian cancer . Br J Cancer. 1998 Jun;77(11): 1870-1874.

[Oehler´99] Oehler MK, Sutterlin M, Caffier H.CASA and Ca 125 in diagnosis and follow-up of advanced ovarian cancer. Anticancer Res. 1999 Jul-Aug;19(4A): 2513-2518.

[Offner`95] Offner FA, Obrist P, Stadlmann S, Feichtinger H, Klingler P, Herold M, Zwierzina H, Hittmair A, Mikuz G, Abendstein B . IL-6 secretion by human peritoneal mesothelial and ovarian cancer cells. Cytokine 1995;7: 542-547.

[Omelyanenko`98] Omelyanenko V, Gentry C, Kopeckova P, Kopecek J. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro. Int J Cancer 1998 Feb 9;75(4): 600-608.

[Omura`91] Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ, Buchsbaum HJ, Park RC. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 1991 Jul;9(7): 1138-1150.


[Seite innerhalb Literaturhinweis 106↓]

[Oruzio`97] Oruzio D, Hempel D, et al Knochenmarkmikrometastasen epithelialer Tumoren, Nachweis und klinische Bedeutung. Onkologe 1997;3: 66-72.

[Osterholzer`85] Osterholzer HO, Streibel EJ, Nicosia SV. Growth effects of protein hormones on cultured rabbit ovarian surface epithelial cells. Biol Reprod. 1985 Aug; 33(1): 247-258.

[Owens´91] Owens NJ, Larat EP, Fretwell MD . Improving compliance in the older patient. In: Cramer JA, Spilker B (eds). Compliance in Medical Practice and Clinical Trials. New York: Raven Press 1991; 323–33.

[Ozols`92] Ozols RF, Rubin SC, Dembo AJ et al Epithelial ovarian cancer. In: Hoskins WJ, Perez CA, Young RC (eds) Gynecologic oncology. Lippincott, Philadelphia 1992;731-781.

[Ozols`99] Ozols RF, Bundy BN, Fowler J et al Randomized phase III study of cisplatin (CIS)/ paclitaxel (PAC) vs. carboplatin (CARBO) / paclitaxel (PAC) in optimal Stage III epithelial ovarian cancer (GOG 158) Proc Am Soc Clin Oncol 1999;18Abstract 1373.

[Ozols`00] Ozols RF. Optimum chemotherapy for ovarian cancer. Int J Gynecol Cancer. 2000 Jan;10(Suppl. 1): 33-37.

[Ozols`02] Ozols RF. Update on the management of ovarian cancer. Cancer 2002;8(Suppl. 1): 22-30.

[Ozols`03] Ozols RF, Bundy BN, Greer BE et al Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003 Sep 1;21(17): 3194-3200.

[Paganoni`03] Paganoni P, Floriani I, Landoni F, Torri V, Buda A, Taraboletti G, Labianca R, Belotti D, Giavazzi R . Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. Eur J Cancer. 2003 Sep;39(13): 1948-1956.

[Paley`97] Paley PJ, Staskus KA, Gebhard K et al Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer. 1997 Jul 1;80(1): 98-106.

[Panici`02] Panici PB, Angioli R. Role of lymphadenectomy in ovarian cancer. Best Practice & Research Clinical Obstetrics and Gynecology 2002;16(4): 529–551.

[Pantel`01] Pantel K, Otte M. Disseminated tumor cells: diagnosis, prognostic relevance, and phenotyping. Recent Results Cancer Res. 2001;158: 14-24.

[Parazzini`99] Parazzini F, Valsecchi G, Bolis G et al Pelvic and paraaortic Lymph nodal status in advanced ovarian cancer and survival Gynecologic Oncology 1999;74: 7-11.

[Parker`94] Parker D, Bradley C, Bogle SM, Lay J, Masood M, Hancock AK, Naylor B, Price JJ. Serum albumin and CA 125 are powerful predictors of survival in epithelial ovarian cancer. Br J Obstet Gynaecol 1994;101: 888-893.

[Parkin`92] Parkin DM, Muir CS, Whelan SF et al Cancer Incidence in Five Continents. IARC Scientif. Lyon, France (eds.) 1992.

[Parmar`03] Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Trope C. ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial Lancet. 2003 Jun 21;361(9375): 2099-2106.

[Pecorelli`98] Pecorelli S, Boyle P, Odicino F, Sideri M Maisonneuve P, Severi G, Zigliani L (eds) FIGO Annual Report on the Results on the Treatment in Gynaecological Cancer. 23rd vol. J Epidemiol Biostat 1998;3: 1–168.


[Seite innerhalb Literaturhinweis 107↓]

[Pecorelli´99] Pecorelli S, Wagenaar HC, Vergote IB et al Cisplatin (P), vinblastine (V) and bleomycin (B) combination chemotherapy in recurrent or advanced granulosa(-theca) cell tumours of the ovary. An EORTC Gynecological Cancer Cooperative Group study. Eur J Cancer 1999;35: 1331-1337.

[Pecorelli`01]Pecorelli S, Benedet J, Beller U, Creasman W, Heintz A, Pettersson F . FIGO Annual Report on the Results of Treatment in Gynaecological Cancer. FIGO Annual Report on the Results of Treatment in Gynaecological Cancer. Oxford, England: Isis Medical Media Ltd, 2001;6: 1-184.

[Peethambaram`03] Peethambaram PP, Cliby WA, Lubiniecki G, Clayton AC, Roche PC, Iturria SJ, Hartmann LC, Hellstrom I, Strome SE. Gynecologic Oncology April 2003;89(1): 99-104.

[Penson`03] Penson et al Attitudes to chemotherapy in patients with ovarian cancer. ASCO 2003;Abstract #1888.

[Peterson`94] Peterson CM, Jolles CJ, Carrell DT, Straight RC, Jones KP, Poulson AM, Hatasaka HH. GnRH agonist therapy in human ovarian epithelial carcinoma (OVCAR-3) heterotransplanted in the nude mouse is characterized by latency and transience. Gynecologic Oncology 1994;52: 26-30.

[Petricoin´02] Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg

SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002 Feb 16;359(9306): 572-577.

[Pettersson`85] Pettersson F, Fotiou S, Einhorn N, Silfversward C. Cohort study of the long-term effect of irradiation for carcinoma of the uterine cervix. Second primary malignancies in the pelvic organs in women irradiated for cervical carcinoma at Radiohemmet 1914-1965. Acta Radiol Oncol 1985;24: 145-151.

[Pfisterer`94] Pfisterer J, Kommoss F, Sauerbrei W et al Cellular DNA content and survival in advanced ovarian carcinoma. Cancer 1994;74: 2509-2515.

[Pfisterer`02] Pfisterer J, Kaye SB, Vasey PA. Docetaxel in ovarian cancer: phase III perspectives and future development. Semin Oncol. 2002 Jun;29(3 Suppl 12): 22-27.

[Pfisterer`03] Pfisterer J, Lortholary A, Kimmig R, et al For the AGO and GINECO Study Groups. Paclitaxel/carboplatin (TC) vs. paclitaxel/carboplatin followed by topotecan (TC-Top) in first-line treatment of ovarian cancer FIGO stages IIb - IV. Interim results of a gynecologic cancer intergroup phase III trial of the AGO Ovarian Cancer Study Group and GINECO. Proc Am Soc Clin Oncol 2003;22 Abstract 1793: 446.

[Piccart`00-1] Piccart M.J, Bertelsen K, James K Cassidy J, Mangioni C et al Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced ovarian cancer. Three year results . J Natl Cancer Inst. 2000;92(9): 699-708.

[Piccart`00-2] Piccart MJ, du Bois A, Gore ME, Pecorelli S, Pujade-Lauraine E. A new standard of care for treatment of ovarian cancer. European Journal of Cancer 2000;36: 10-12.

[Pignata`03] Pignata S, Deplacido S, Scambia G et al For the MITO Investigators; Topotecan vs nihil after response to carboplatin and paclitaxel in advanced ovarian cancer. Early results of the MITO-1 (Multicenter Italian Trials in Ovarian Cancer) study. Proc Am Soc Clin Oncol 2003;22: 446 Abstract 1791.

[Pike`00] Pike MC, Spicer DV. Hormonal contraception and chemoprevention of female cancers . Endocrine-related cancer 2000;7: 73-83.

[Pisa`92] Pisa P, Halapi E, Pisa EK, Gerdin E, Hising C, Bucht A, Gerdin B, Kiessling R. Selective expression of interleukin 10, interferon gamma, and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies. Proc. Natl. Acad. Sci. USA 1992;89: 7708-7712.

[Plante`94] Plante M, Rubin SC, Wong GY, Federici MG, Finstad CL, Gastl GA. Interleukin-6 level in serum and scites as a prognostic factor in patients with epithelial ovarian cancer. Cancer. 1994;73: 1882-1888.

[Poels`89] Poels LG, Ramaekers F, Scheres J, Thomas C. Characterization of a hormone-producing ovarian carcinoma cell lone. Gynecologic Oncology 1989;32: 203-214.


[Seite innerhalb Literaturhinweis 108↓]

[Puls`96] Puls LE, Duniho T, Hunter JE, Kryscio R, Blackhurst D, Gallion H. The Prognostic Implication of Ascites in Advanced-Stage Ovarian Cancer. Gynecologic Oncology 1996 Apr;61(1): 109-112.

[Purdie`95] Purdie D, Green A, Bain C, Siskind V, Ward B, Hacker N et al Reproductive and other factors and risk of epithelial ovarian cancer: an Australien case-control study. Int. J. Cancer 1995;62: 678-684.

[Purdie`99} Purdie D, Bain C, Siskind V, Russell P, Hacker N, Ward B, Quinn M, Green A. Hormone replacement therapy and risk of epithelial ovarian cancer. Br J Cancer 1999;82:625-629.

[Purdie`03] Purdie DM, Bain CJ, Siskind V, Webb PM, Green AC. Ovulation and risk of epithelial ovarian cancer . Int J Cancer. 2003 Mar 20;104(2 ): 228-232.

[Quade`02] Quade G. Prevention of ovarian cancer. University of Bonn, Medical Center 2002.

[Radke`96] Radke J, Schmidt D, Bohme M, Schmidt U, Weise W, Morenz J. Zytokinspiegel im malignen Aszites und peripheren Blut von Patientinnen mit fortgeschrittenem Ovarialkarzinom. Geburtshilfe Frauenheilkd. 1996;56: 83-87.

[Rahaman`01] Rahaman J, Jennings TS, Dottino P, Cohen CJ. Mount Sinai Medical Center, New York, NY; Charleston, SC; New York, NY: Impact of Age on Survival in Advanced Ovarian Cancer: a Re-Examination.. Proceedings of ASCO unter www.asco.org. 2001;Abstract 866.

[Rahaman`02] Rahaman J, Cohen C. Impact of aszites on survival in advanced ovarian cancer. 38th ASCO Annual Meeting 2002;Abstract 837.

[Rakar`90] Rakar S, Kovacic J, Cavic M, Lukanovic A, Mozina A. Prognostic factors in ovarian cancer. Eur J Gynecol Oncol 1990;11(3):171-173.

[Redler-Hasford´85] Redler-Hasford E, van Eimeren W, Tritschler J. Warum sind Krebs-patienten aufgeschlossen für unkonventionelle Behandlungsmethoden? Erfahrungsheilkunde. 1985;10: 759-769.

[Reles`95] Reles A, Press MF, Schönborn I, Lichtenegger W. Strohmeyer, T .: p53 Proteinuberexpression in Ovarialkarzinomen: Korrelation mit histopathologischen Daten und klinischem Verlauf. Gynäkol. Geburtshilfliche Rundsch. 1995;35(Suppl 1): 93-97.

[Reles`97] Reles A, Wein U, Lichtenegger W. Transvaginal color Doppler sonography and conventional sonography in the preoperative assessment of adnexal masses. J Clin Ultrasound 1997;25: 217-225.

[Reles`99] Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, Jones LA, El-Naggar A, Minguillon C, Schonborn I, Reich O, Kreienberg R, Lichtenegger W. Press MF.p53 mutations and expression in ovarian cancers: correlation with overall survival Int J Gynecol Pathol. 1999 Jan;18(1): 29-41.

[Rendina`82] Rendina GM, Donadio C, Giovanni M. Steroid receptors and progestinic therapy in ovarian endometroid carcinoma. Eur J Gynecol Oncol 1982;3: 241.

[Ricke`99] Ricke J, Sehouli J, Hosten N, Stroszczynski C, Amthauer H, Rieger J, Buchmann E, Felix R. Fat-saturated, contrast-enhanced spin-echo sequences in the magnetic resonance tomographic diagnosis of peritoneal carcinosis. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 12/1999;171(6): 461-467.

[Ricke`03] Ricke J, Sehouli J, Hach C, Hänninen EL, Lichtenegger W, Felix R. Prospective evaluation of contrast-enhanced MRI in the depiction of peritoneal spread in primary or recurrent ovarian cancer. Epub 2002 Nov 05. Eur Radiol. 5/2003;13(5): 943-949.

[Riman`98] Riman T, Persson I, Nilsson S. Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence. Clin Endocrinol 1998;49:695-707.

[Rioux `95] Rioux M, Michaud C. Sonographic detection of peritoneal carcinomatosis: a prospective study of 37cases. Abdom Imaging 1995;20: 47-51.


[Seite innerhalb Literaturhinweis 109↓]

[Risch`94] Risch HA, Jain M, Marrett LD, Howe GR. Dietary lactose intake, lactose intolerance, and the risk of epithelial ovarian cancer in southern Ontario (Canada). Cancer Causes Control 1994;5: 540-548.

[Rodriguez`95] Rodriguez C, Calle EE, Coates RJ, Miracle MC Mahill HL, Thun MJ, Heath CW. Estrogen replacement therapy and fatal ovarian cancer. Amer J Epidemiol 1995;141: 828-835.

[Rodriguez`01] Rodriguez C, Patel A, Calle E, Jacob E, Thun M . Estrogen replacement therapy and ovarian cancer mortality in large prospective study of US women. JAMA 2001;285 : 1460-1465.

[Rodriguez`02] Rodriguez IM, Prat J. Mucinous tumors of the ovary. A clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas. Am J Surg Pathol 2002;26: 139-152.

[Ronay´89] Ronay G, Jager W, Tulusan AH. Immunohistochemical and serologic detection of Ca-125 in patients with peritoneal tuberculosis and ascites. Geburtshilfe Frauenheilkd. 1989 Jan;49(1): 61-63.

[Rose`02] Rose PG, Nerenstone S, Brady M et al A phase III randomized study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease: a gynecologic Oncology Group study. 38th ASCO Annual Meeting 2002;Abstract 802.

[Rossing`94] Rossing M, Daling J, Weiss N, Moore D, Self S. Ovarian tumors in a cohort of infertile women. N Engl J Med 1994 Sept.22;331(12): 771-776.

[Roszkowski`93] Roszkowski P, Wronkowski Z, Szamborski J et al Evaluation of selected prognostic factors in ovarian cancer. Eur J Gynaecol Oncol. 1993;14 Suppl: 140-145.

[Rothenberg`02] Rothenberg ML, Liu P, Wilctynski S et al Excellent 2-year survival in women with optimally-debulked ovarian cancer treated with intraperitoneal and intravenous chemotherapy: a SWOG-ECOG-NCIC study (S9619). 38th ASCO Annual Meeting 2002;Abstract 809.

[Rowinsky´96] Rowinsky EK, Kaufmann SH, Baker SD, Grochow LB, Chen TL, Pereboom D, Bowling MK, Sartorius SE, Ettinger DS, Forastiere AA, Donehower RS. Sequences of topotecan and cisplatin: phase I, pharmacologic and in vitro studies to examine sequence dependence. J Clin Oncol. 1996 Dec;14(12): 3074-3084.

[Rubin`91] Rubin SC, Hoskins WJ, Saigo PE, Chapman D, Hakes TB, Markman M, Reichman B, Almadrones L, Lewis JL. Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy. Gynecol Oncol 1991;42 : 137-141.

[Rubin`99] Rubin SC, Randall TC, Armstrong KA, Chi DS, Hoskins WJ. Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet Gynecol 1999;93: 21-24.

[Runnebaum`98] Runnebaum IB, Mollenkopf A, Kreienberg R, Meerpohl HG. Epidemiologische und molekulargenetische Risikofaktoren beim Ovarialkarzinom. Onkologe 1998;4: 1096-1100.

[Saksela`93] Saksela E. Prognostic markers in epithelial varian cancer. Int J Gynecol Pathol 1993;12(2):156-161.

[Sakurai`01] Sakurai S, Shimizu Y, Utsugi K et al Validity of complete paraaortic and pelvic lymphadenectomy in apparent stage I (pT1) ovarian carcinoma. 38th ASCO Annual Meeting 2002;Abstract 801.

[Sakurai`02] Sakurai S, Shimizu Y, Utsugi K, Umezawa S, Kato T, Fukasawa I, Inaba N, Hasumi K. Validity of complete paraaortic and pelvic lymphadenectomy in apparent stage I (pT1) ovarian carcinoma. 38th ASCO Annual Meeting 2002;Abstract 801.


[Seite innerhalb Literaturhinweis 110↓]

[Sandercock`02] Sandercock J, Parmar MK, Torri V, Qian W. First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence. Br J Cancer. 2002 Oct 7;87(8): 815-824.

[Santin`95] Santin AD, Ioli GR, Hiserodt JC, Rose GS, Graf MR, Tocco LM, Lander JK, Eck LM, Burger RA, DiSaia PJ. Development and characterization of an IL-4-secreting human ovarian carcinoma cell line. Gynecol. Oncol. 1995;58: 230-239.

[Sapi`02] Sapi E, Okpokwasili NI, Rutherford T. Detection of telomerase-positive circulating epithelial cells in ovarian cancer patients. Cancer Detect Prev. 2002;26(2): 158-167.

[Savage´98] Savage P, Constenla D, Fisher C et al Granulosa cell tumors of the ovary: Demographics, survival and the management of advanced disease. Clinical Oncology 1998;10: 242-245.

[Scarfone ´01] Scarfone G, Parazzini F. Sciatta C. et al Multicenter Randomized Trial Comparing Two Different Doses of Taxol (T) Plus a Fixed Dose of Carboplatin (C) in Advanced Ovarian Cancer (AOC). 2001 ASCO Annual Meeting;Abstract 816.

[Scambia`94] Scambia G, Testa U, Panici PB, Martucci R, Foti E, Petrini M, Amoroso M, Masciullo V, Peschle C, Mancuso S. Interleukin-6 serum levels in patients with gynecological tumors . Int. J. Cancer. 1994;57: 318-323.

[Scambia`95] Scambia G, Testa U, Benedetti-Panici P, Foti E, Martucci R, Gadducci A, Perillo A, Facchini V, Peschle C, Mancuso S. Prognostic significance of interleukin-6 serum levels in patients with ovarian cancer. Br. J. Cancer. 1995;71: 354-356.

[Scarabelli`95] Scarabelli C, Gallo A, Zarrelli A, Visentin C, Campagnutta E. Systematic pelvic and para-aortic lymphadenectomy during cytoreductive surgery in advanced ovarian cancer: potential benefit on survival Gynecol Oncol 1995;56: 328-227.

[Scharf`02] Scharf A, Günter HH, S Sohn. Screening auf Ovarialkarzinom. Der Gynäkologe 2002;35: 537-547.

[Schelling`01] Schelling M, de Waal JC. Präoperative Diagnostik, Diagnosesicherung. In Kuhn: Manual maligne Ovarialtumoren Empfehlungen zur Diagnostik, Therapie und Nachsorge. Tumorzentrum München 2001;14-15.

[Scheuermann`97] Scheuermann W, Rensing K, Schmid H, Wallwiener D, Bastert G. Mortalität an bösartigen Brust- und Genitaltumoren bei Frauen in der Bundesrepublik Deutschland von 1970-1994. Geburtsh. U. Frauenheilk. 1997;57: 423-428.

[Schiffenbauer`97] Schiffenbauer YS, Abramovitch R, Meir G, Nevo N, Holzinger M, Itin A, Keshet E, Neeman M. Loss of ovarian function promotes angiogenesis in human ovarian carcinoma. Proc Natl Acad Sci USA 1997;94: 13203-13208.

[Schilder`03] Schilder et al Phase II trial of gefitinib in patients with recurrent ovarian or primary peritoneal cancer. Gynecology Oncology Group 170c. ASCO 2003;Abstract #1814.

[Schildkraut`00] Schildkraut JM, Halabi S, Bastos E, Marchbanks PA, McDonald JA, Berchuck A . Prognostic Factors in Early-Onset Epithelial Ovarian Cancer: A Population-Based Study. Obstet Gynecol 2000;95: 119-127.

[Schmalfeldt`01] Schmalfeldt B, Prechtel D, Harting K, Spathe K, Rutke S, Konik E, Fridman R, Berger U, Schmitt M, Kuhn W, Lengyel E. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res. 2001 Aug;7(8): 2396-2404.

[Schmider`00] Schmider A, Gee C, Friedmann W, Lukas JJ, Press MF, Lichtenegger W, Reles A. P21 (WAF1/CIP1) protein expression is associated with prolonged survival but not with p53 expression in epithelial ovarian carcinoma. Gynecol Oncol. 2000 May;77(2): 237-242.

[Schneider`97] Schneider D, Halperin R, Langer R, Bukovsky I, Herman A. Peritoneal Fluid Lactate Dehydrogenase in Ovarian Cancer. Gynecologic Oncology 1997;66: 339-404.


[Seite innerhalb Literaturhinweis 111↓]

[Schneider`98] Schneider D, Halperin R, Halperin D, Bukovsky I, Hadas E. Prediction of the survival of patients with advanced ovarian cancer according to a risk model based on a scoring system. Eur J Gynaecol Oncol 1998;19: 547-552.

[Schönborn`96] Schönborn I, Minguillon C, Reles ., Bartel U, Lichtenegger W . Die Bedeutung der PCNA-Proliferationsfraktion fur die Prognose des Ovarialkarzinoms. Geburtshilfe Frauenheilkd. 1996;56: 357-364.

[Schondorf``97] Schondorf T, Engel H, Lindemann C, Kolhagen H, von-Rucker, AA, Mallmann P. Cellular characteristics of peripheral blood lymphocytes and tumour-infiltrating lymphocytes in patients with gynaecological tumours. Cancer Immunol. Immunother. 1997;44: 88-96.

[Schroder`94] Schroder W, Ruppert C, Bender HG. Concomitant measurements of interleukin-6 (IL-6) in serum and peritoneal fluid of patients with benign and malignant ovarian tumors. Eur. J. Obstet. Gynecol. Reprod. Biol. 1994;56: 43-46.

[Schouten et al/03] Schouten LJ, Goldbohm RA, van den Brandt PA. Height, weight, weight change, and ovarian cancer risk in the Netherlands cohort study on diet and cancer. Am J Epidemiol. 2003 Mar 1;157(5): 424-433.

[Schwartz`95] Schwartz PE, Chambers JT, Taylor KJ. Early detection and screening for ovarian cancer. J Cell Biochem 1995;Suppl 23: 233-237.

[Scully`88] Scully RE, Silva E. Pathology of ovarian cancer. In Gersheson GM, McGuire WP (HRSG). Ovarian Cancer. Controversies in management. Churchill Livingstone, New York Edinburgh London Madrid Melbourne San Francisco Tokio 1988;425-444.

[Scully`99] Scully RE, Sobin LH. World Health Organisation (WHO). International histological classification of tumours. Histological typing of ovarian tumors. Springer Berlin Heidelberg 1999.

[Scully`02] Scully RE . Influence of origin of ovarian cancer on efficacy of screening. The Lancet 2002;355: 1028–1029.

[Sehouli`98] Sehouli J, Horstkamp B, Schonborn I, Kettner H, Lichtenegger W. Prospective, randomised phase II trial: carboplatin and oral etoposide versus carboplatin and cyclophosphamide in the first-line treatment of ovarian cancer. 17th International Cancer congress 1998;1259-1263.

[Sehouli`00-1] Sehouli J, David M, Kaufmann B, Lichtenegger W. Unkonventionelle Methoden in der Krebsmedizin-Postoperative Nutzung durch Patientinnen mit gynäkologischen Malignomen. Geburtsh Frauenheilk 2000;60: 147-154.

[Sehouli`00-2] Sehouli J, Kopetsch OJ, Ricke J, Buchmann E, Stengel D, Riess H, Weidemann H, Schaper F, Freiesleben W, Lichtenegger W. Primary Mucinous Adenocarcinoma of the appendix: A rare entity in the differential diagnosis of ovarian cancer. Journal Obstet. Gynaecol. Res. 10/2000;26(5):333-339.

[Sehouli`01] Sehouli J, Stengel D, Hindenburg, Camara O, Porzsolt F, Lichtenegger W. Herausforderung Evidence-based Medicine: Sinn und Unsinn diagnostischer Tests in der Gynäkologie . Zentralblatt für Gynäkologie 2001;123: 127-131.

[Sehouli`02-1] Sehouli J, Lichtenegger W, Hauptmann S, Dietel D. Therapie von Borderline-Tumoren des Ovars. Frauenarzt 2002;43(10 ): 1202-1207.

[Sehouli`02-2] Sehouli J, Mustea A, Könsgen D, Katsares I, Lichtenegger W. Polymorphism of IL-1Receptor Antagonist Gene: Role in Cancer. Anticancer Research 2002; 22: 3421-3424.

[Sehouli`02-3] Sehouli J, Stengel D, Elling D, Ortmann O, Blohmer J, Riess H, Lichtenegger W. First-line chemotherapy with weekly paclitaxel and carboplatin for advanced ovarian cancer: a phase I study. Ovarian Cancer Study Group of the Nordostdeutsche Gesellschaft fur Gynakologische Onkologie (NOGGO). Gynecol Oncol. 2002 May;85(2): 321-326.

[Sehouli`02-4] Sehouli J, Stengel D, Drzewiecki K et al Weekly taxol (T) and paclitaxel (P) as first-line therapy in advanced ovarian cancer (AOC): a phase II Study. 38th ASCO Annual Meeting 2002;Abstract 811.


[Seite innerhalb Literaturhinweis 112↓]

[Sehouli`02-5] Sehouli J, Stengel D, Oskay G, Camara O, Hindenburg HJ, Klare P, Blohmer J, Heinrich G, Elling D, Ledwon P, Lichtenegger W. A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy. Ann Oncol. 11/2002;13(11): 1749-1755.

[Sehouli´02-6] Sehouli J, Stengel D, David M, Alexandre M, Oskay G, Könsgen D, Katsares I, Lichtenegger W. Use of unconventional cancer treatments (UCT) among patients with gynaecologic malignancies in Angola. Journal of Clinical Research and Clinical Oncology 2002;128(Suppl) Abstract #P:595.

[Sehouli´03-1] Sehouli J, Akdogan Z, Heinze T, Könsgen D, Stengel D, Mustea A, Lichtenegger W. Preoperative Determination of CASA (Cancer Associated Serum Antigen) and CA-125 for the Discrimination between Benign and Malignant Pelvic Tumor Mass: A Prospective Study. Anticancer Research 2003 Mar-Apr;23(2A): 1115-1118.

[Sehouli´03-2] Sehouli J, Könsgen D, Nimpsch R, Oskay G, Stengel D, Oertel J, Lichtenegger W, Mustea A. Detection of Epithelial Carcinoma Cells in the Blood of Patients with Gynaecological Malignancies. Anticancer Research 2003 Mar-Apr;23(2A): 1093-1097.

[Sehouli`03-3] Sehouli J, Drescher F, Mustea A, Nehmzow M, Friedmann W, Kühn W, Elling D, Klare P, Lichtenegger W. Stellenwert der systemischen Chemotherapie beim Granulosazelltumor des Ovars: Eine Langzeitanalyse von 25 Patientinnen. Geburtsh Frauenheilk 2003;529-537.

[Sehouli`03-4] Sehouli J, Könsgen D, Mustea A, Oskay-Özcelik G, Katsares I, Weidemann H, Lichtenegger W. "IMO" - Intraoperative Mapping of Ovarian Cancer Zentralbl Gynakol. 2003 Mar-Apr;125(3-4): 129-135.

[Sehouli`03-5] Sehouli J, Könsgen D, Steinmüller K, Lichtenegger W. Management des Ovarialkarzinoms im Jahr 2010 - Ergebnisse einer Umfrage an 100 Patientinnen. Geburtshilfe und Frauenheilkunde. 2003;63: 230-234.

[Sehouli´03-6] Sehouli J, Mustea A, Koensgen D, Chen FC, Lichtenegger W . Interleukin-1 receptor antagonist gene polymorphism is associated with increased risk of epithelial ovarian cancer. Ann Oncol. 2003 Oct;14(10): 1501-1504.

[Sehouli`03-7] Sehouli J, Lichtenegger W. Kommentar zur Publikation: International Collaborative Ovarian Neoplasm Group. Gyn 2003 ;(8): 196-197.

[Sehouli`03-8] Sehouli J, Mustea A, Koensgen D, Lichtenegger W . Interleukin-1 Receptor Antagonist Gene Polymorphism in Epithelial Ovarian Cancer. Cancer Epidemiology Biomarkers & Prevention 2003 Nov.; 12(11 pt 1): 1205-1208.

[Sehouli`03-9] Sehouli J, Könsgen D, Klapp C, Walle U, Katsares I, Oskay G, Mustea A, Bühling K, Lichtenegger W. Lebensqualität in der gynäkologischen Onkologie. Geburtsh Frauenheilk 2003;63: 752–757.

[Sehouli´03-10] Sehouli J, Mustea A, Könsgen D, Stengel D, Sofroni D, Lichtenegger W. Interleukin 1 Receptor Antagonist (IL-1RA) Polymorphism in Women with Cervical Cancer. Anticancer Research 2003 Mar-Apr.; 23(2A): 1099-1102.

[Sehouli´03-11] Sehouli J. Möglichkeiten und Grenzen der Diagnostik des Ovarialkarzinoms. Journal Onkologie, 01/2003;4-6.

[Sehouli´03-12] Sehouli J, Lichtenegger W. Kommentar zur Publikation: International Collaborative Ovarian Neoplasm Group. Gyn 2003 ;(8): 196-197.

[Sehouli`04-1] Sehouli J, Drescher FS, Mustea A, Elling² D, Friedmann M, Kühn W, Nehmzow M, Opri F, Klare P, Lichtenegger W. Year Follow Up Data of 65 Patients With Granulosa Cell Tumor Of The Ovary. Anticancer Recearch, in press; 2004.

[Sehouli`04-2] Sehouli J, Oskay G, Stengel D et al Phase I Trial of Topotecan in Combination with Gemcitabine in the Treatment of Patients with Recurrent Ovarian Cancer after Failure of First-line Chemotherapy with Paclitaxel and Platinum. International Journal for Cancer Research and Treatment 2004 Feb;27(1): 58-64.


[Seite innerhalb Literaturhinweis 113↓]

[Sehouli´04-3] Sehouli J, Kostromitskaia J, Stengel D, du Bois A. The physician’s view of reasons of non-participating in clinical trials of ovarian cancer – Results of a prospective AGO-NOGGO-study in Germany 2003. Journal of Cancer Research and Clinical Oncology 2004;130 PO594: 127.

[Sevelda`85] Sevelda P, Salzer H, Gitsch E, Karrer K. Results of the 1st Austrian ovarian cancer study: prospective randomized comparison of a new sequential chemotherapy with 2 standard regimens in 150 stage III and IV patients] Onkologie. 1985 Dec;8(6): 388-391.

[Sevelda`90] Sevelda P, Vavra N, Schemper M et al Prognostic factors for survival in stage I epithelial ovarian carcinoma. Cancer 1990;65: 2349-2352.

[Shen-Gunther´02] Shen-Gunther J, Mannel RS. Ascites as a predictor of ovarian malignancy. Gynecol Oncol. 2002 Oct;87(1): 77-83.

[Shepherd`89] Shepherd JH. Revised FIGO staging for gynaecological cancer. Br J Obstet Gynaecol 1989;96(8): 889-892.

[Shimizu`98] Shimizu Y, Kamoi S, Amada S, Akiyama F, Silverberg SG. Toward the development of a universal grading system for ovarian epithelial carcinoma: Testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer 1998;82: 893–901.

[Shirey`85] Shirey DR, Kavanagh JJ Jr, Gershenson DM et al Tamoxifen therapy of epithelial ovarian cancer. Obstet Gynecol 1985;66: 575.

[Shu`89] Shu XO, Gao YT, Yuan JM, Ziegler RG, Brinton LA. Dietary factors and epithelial ovarian cancer. Br J Cancer. 1989 Jan;59(1): 92-96.

[Shushan`96] Shushan A, Elchalal U, Paltiel O, Peretz T, Iscovich J, Schenker J. Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertil Steril 1996;65: 13-18.

[Silverberg`89] Silverberg SG. Prognostic significance of pathologic features of ovarian carcinoma (Review). Current Topics Pathol 1989;78: 85-109.

[Simojoki`99] Simojoki M, Santala M, Vuopala S, Kauppila A. The prognostic value of peritoneal cytology in ovarian cancer. Eur J Gynecol Oncol 1999;20(5-6): 357-360.

[Slevin`87]Slevin ML, Harvey VJ, Alberts DS, Surwit EA et al Tamoxifen therapy in recurrent eoithelial ovarian carcinoma. Gynecol Oncol 1987;27: 208.

[Slevin´89] SlevinML, Clark PJ, Joel SP et al A randomised trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 1989;7:1333-1340.

[Sliutz`96] Sliutz G. Prognosefaktoren beim Ovarialkarzinom. Wien-Med-Wochenschr. 1996;146: 14-17.

[Slotman`90] Slotman BJ. Rationale for the use of endocrine therapy in ovarian cancer. Thesis Publisher , Amsterdam 1990.

[Slovin`98] Slovin SF, Scher HI. Detectable tumor cells in the blo o d and bone marrow; smoke or fire? Cancer 1998 August 1;3(83): 394-398.

[Smith`93] Smith DR, Kunkel SL, Standiford TJ, et al The production of interleukin 1 receptor antagonist by human bronchogenic carcinoma. Am J Pathol 1993;143: 794-803.

[Smyth`85] Smyth RD, Pfeffer M, Scalzo A et al: Bioavailibilty and pharmacocinetics of etoposide (VP-16). Semin Oncol 1985 ;(Suppl 2) 12. 48-51.

[Sonmezer`04] Sonmezer M, Gungor M, Ensari A, Ortac F. Prognostic significance of tumor angiogenesis in epithelial ovarian cancer: In association with transforming growth factor beta and vascular endothelial growth factor . Int J Gynecol Cancer. 2004 Jan-Feb;14(1): 82-88.

[Sowter`97] Sowter HM, Corps AN, Evans AL, Clark DE, Charnock-Jones DS, Smith SK. Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors. Lab Invest. 1997 Dec;77(6): 607-614.


[Seite innerhalb Literaturhinweis 114↓]

[Stadel`75] Stadel BV. The etiology and prevention of ovarian cancer. American Journal of Obstetrics and Gynecology 1975;123: 772–774.

[Stewart`00] Stewart DE, Wong F, Cheung AM et al Information needs and ecisional

preferences among women with ovarian cancer. Gynecol Oncol 2000;77(3): 357-361.

[Stiff`00] Stiff PJ, Veum-Stone J, Lazarus HM, Ayash L, Edwards JR, Keating A, Klein JP, Oblon DJ, Shea TC, Thome S, Horowitz MM. High-dose chemotherapy and autologous stemm-cell transplantation for ovarian cancer: an autologous blood and marrow transplant registry report. Ann Intern Med 2000;133: 504-515.

[Stimpfl`99] Stimpfl M, Schmid BC, Obermair A, Tong D, Schiebel I, Gitsch G, Leodolter S, Zeillinger R. Comparison of flow cytometry and RT-PCR for the detection of ovarian cancer cells in peripheral blood. Oncol Res. 1999;11(8): 367-373.

[Sun`02]Sun CC, Bodurka DC, Donato et al Patients preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time ? Gynecol Oncol 2002;87(1): 118-128.

[SEER´04] Surveillance Epidemiology and End Results (SEER) Program (www.seer.cancer.gov). National Cancer Institute (NCI).

[Takano`02] Takano H, Okamoto A, Fukushima K, Ochiai K, Tanaka T. Low specificity of cytokeratin 19 mRNA expression in the peripheral blood cells from patients with ovarian tumors. Oncol Rep. 2000 Sep-Oct;7(5): 1023-1025.

[Tattersall`02] Tattersall M. Ovarian cancer chemotherapy: carboplatin as standard . Lancet 2002;360:500-501.

[Taylor`99] Taylor AE, Olver IN, Sivanthan T, Chi M, Purnell C. Observer error in grading performance status in cancer patients. Supportive Care in Cancer 1999;7: 332-335.

[Tempany`98] Tempany CM, Zou KH, Silverman SG, Brown DL, Kurtz AB, McNeil BJ. Staging of ovarian cancer in the peritoneum, lymphnodes and liver:comparison of imaging modalities - a report from the RDOG group. Radiology [Suppl] RSNA abstract book 1998;209:258.

[Tempfer`97] Tempfer C, Zeisler H, Sliutz G, Haeusler G, Hanzal E, Kainz C. Serum evaluation of interleukin 6 in ovarian cancer patients. Gynecol. Oncol . 1997;66: 27-30.

[Tempfer`98] Tempfer C, Obermair A, Hefler L et al Vascular endothelial growth factor serum concentration in ovarian cancer. Obstet Gynecol 1998;92: 360-363.

[Terry`03] Terry PD, Miller AB, Jones JG, Rohan TE. Cigarette smoking and the risk of invasive epithelial ovarian cancer in a prospective cohort study. Eur J Cancer. 2003 May;39(8): 1157-1164

[Testa`94] Testa JR, Getts LA, Salazar H, Liu Z, Handel LM, Godwin AK, Hamilton TC. Spontaneous transformation of rat ovarian surface epithelial cells results in well to poorly differentiated tumors with a parallel range of cytogenetic complexity. Cancer Res. 1994 May 15;54(10):2778-2784.

[Teufel`76] Teufel G, Pfleiderer A. Geburtshilfe Ifosfamide in comparison with cyclophosphamide in advanced ovarian carcinomas Frauenheilkd. 1976 Mar;36(3 ): 274-279.

[Thelen`90] Thelen M, Leicher-Duber A, Schayan K, Schweden F. Bildgebende Diagnostik der Peritonealkarzinose. Fortschr Röntgenstr 1990;152: 654-661.

[Thigpen`93] Thigpen T, Brady MF, Omura GA, Creasman WT, McGuire WP, Hoskins WJ, Williams S. Age as prognostic factor in ovarian carcinoma. Cancer 1993;71: 606-614.

[Thompson`88] Thompson MA, Adelson MD, Kaufaran LM, Marshall LD, Cable DA. Aromatization of testerone by epithelial tumor cells cultured from patients with ovarian carcinoma. Cancer Res 1988;48: 6491-6497.


[Seite innerhalb Literaturhinweis 115↓]

[Thomssen`02] Thomssen C, Meier W. Rezidivchirurgie beim Ovarialkarzinom. Indikationen und Möglichkeiten. Der Onkologe 2002;8:1216-1221.

[Trimble`01] Trimble EL. Prospects for improving staging of ovarian cancers. Lancet 2001;357: 159-160.

[Trimbos`03-1] Trimbos JB, Vergote I, Bolis G et al Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial J Natl Cancer Inst. 2003 Jan 15;95(2): 113-125.

[Trimbos`03-2] Trimbos JB, Parmar M, Vergote I et al International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst. 2003 Jan 15;95(2): 105-112.

[Trope`00] Trope C, Kaern J, Hogberg T et al Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument. Ann Oncol. 2000;11(3): 281-288.

[Tsuruchi`93] Tsuruchi N, Kamura T, Tsukamoto N, Akazawa K et al Relationship between Paraaortic Lymph Node Involvement and Intraperitoneal Spread in Patients with Ovarian Cancer-a multivariate Analysis. Gynecol Oncol 1993;49: 51-55.

[UICC`97] UICC: TNM Classification of malignant tumors. Sobin LH, Wittekind C (eds). Wiley-Liss, New York 1997.

[Unfried´01] Unfried G, Tempfer C, Schneeberger C, Widmar B, Nagele F, Huber JC. Interleukin 1 receptor antagonist polymorphism in women with idiopathic recurrent miscarriage. Fertil Steril. 2001;75(4): 683-687.

[Valter`99] Valter MM, Wiestler OD, Pietsche T, Pietsch T. Differential control of VEGF synthesis and secretion in human glioma cells by IL-1and EGF. Int J Dev Neurosci. 1999 Aug-Oct;17(5-6): 565-577.

[van der Burg`88] van der Burg MEL, Lammes FB, Van Putten WLJ et al Ovarian cancer: the half-life of CA125 during induction chemotherapy. Gynecol Oncol 1988;30: 307-312

[van der Burg`90] van der Burg MEL, Lammes FB, Verweij J et al The role of CA125 in the early diagnosis of progresive disease in ovarian cancer. Ann Oncol 1990;1: 301-302.

[van der Burg`92] van der Burg ME, Lammes FB, Verweij J. CA 125 in ovarian cancer. Neth J Med. 1992 Feb;40(1-2): 36-51.

[van der Burg`95] van der Burg ME, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, Lacave AJ, Nardi M, Renard J, Pecorelli S. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med. 1995 Mar 9;332(10): 629-634.

[van der Burg`01] Burg van der ME. Advanced ovarian cancer. Curr-Treat-Options-Oncol. 2001 Apr;2(2): 109-118.

[van der Zee`95] van der Zee AG, de Cuyper EM, Limburg PC, de-Bruijn HW, Hollema H, Bijzet J, Krans M, de Vries EG. Higher levels of interleukin-6 in cystic fluids from patients with malignant versus benign ovarian tumors correlate with decreased hemoglobin levels and increased platelet counts. Cancer. 1995;75: 1004-1009.

[Van Le`91] Van Le L, Haskill S, Jaffe GJ and Fowler WC. Expression of interleukin 1 and interleukin 1 receptor antagonist in endometrial cancer. Gynecol Oncol 1991;42: 161-164.

[van Nagell`00] van Nagell JR, De Priest PD, Reedy MB, Gallion HH, Ueland FR, Pavlik EJ, Kryscio RJ. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gyncol Oncol 2000;77: 350-356.

[Vavra´89] Vavra N, Sevelda P, Dittrich CH et al Carboplatin/etoposide as first line and second line treatment in patients with ovarian cancer. Proceedings of the Second Meeting of the international Gynecologic Cancer Society, Toronto, Ontario, Canada, 1989 October 9.


[Seite innerhalb Literaturhinweis 116↓]

[Vasey`02] Vasey PA. On behalf of the Scottish Gynaecological Cancer Trials Group: Survival and longer-term toxicity results of the SCOTROC study: docetaxel-carboplatin (DC) vs. paclitaxel-carboplatin (PC) in epithelial ovarian cancer (EOC). 38th ASCO Annual Meeting 2002;Abstract 804.

[Venn`95] Venn A, Watson L, Lumley J, Giles G, King C, Healy D. Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet 1995;346: 995-1000.

[Venn`99] Venn A, Watson L, Bruinsma F, Giles G, Healy D. Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet 1999;354: 1586-1590.

[Vergote`87] Vergote IB, Bormer OP, Abeler VM. Evaluation of serum CA125 levels in the monitoring of ovarian cancer. Am J Obstet Ginecol 1987;157: 88-92.

[Vergote`93] Vergote IB, Kaern J, Abeler V et al Analysis of prognostic factors in stage I epithelial ovarian cancer: Importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse. Am J Obstet Gynecol 1993;169: 40-52.

[Vergote`01] Vergote IB, De Brabanter J, Fyles A. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet. 2001 Jan 20;357(9251 ): 176-182.

[Verheijen`85] Verheijen RH, Beex L, Wagener DJ, Kenemans P. Cis-platin in combination with low dose adriamycin and cyclophosphamide in advanced ovarian carcinoma. Eur J Gynaecol Oncol. 1985;6(2): 116-120.

[Vessey`95] Vessey M, Painter R. Endometrial and ovarian cancer and oral contraceptives- findings in a large cohort study. Br J Cancer 1995;71: 1340-1342.

[Wagner`01] Wagner U, Blohmer JU, Lück HJ. Medikamentöse Rezidivtherapie, Der Gynäkologe 2001;34: 1020-1023.

[Walkey´88] Walkey MM, Friedman AC, Sohotra P, Radecki PD. CT manifestations of peritoneal carcinomatosis. Am J Roentgenol 1988;150: 1035-1041.

[Wallberg´00] Wallberg B, Michelson H, Nystedt M et al Information needs and preferences for participation in treatment decisions among Swedish breast cancer patients. ActaOncol 2000;39: 467-476.

[Walter`99] Walter AJ, Magrina JF. Contralateral pelvic and aortic lymph node metastasis in clinical stage I epithelial ovarian cancer. Gynecologic Oncology 1999;74: 128-129.

[Watson`90] Watson JM, Sensintaffar JL, Berek JS, Martinez-Maza O . Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Res. 1990;50: 6959-6965.

[Watson`93] Watson P, Lynch HT. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 1993;71: 677-685.

[Watson`95] Watson JM, Lofquist AK, Rinehart CA, Olsen JC, Makarov SS, Kaufman DG, Haskill JS. The intracellular IL-1receptor antagonist alters IL-1-inducible gene expression without blocking exogenous signaling by IL-1beta. J. Immunol. 1995;155: 4467-4475.

[Weblus`04] Weblus A, Fischer A, Klapp C, Sehouli J, Lichtenegger W. Wertigkeit funktioneller Musik während der zytostatischen Therapie-Eine prospektive Phase I/II Studie. Zentralbl Gynakol 2004;126(56) Abstract P21.

[Weidemann`03] Weidemann H, Hieronimus-Reichel A, Sehouli J, Platz KP, Buchmann E, Heider B, Lichtenegger W 2, Loening SA 3, Neuhaus P. Multivisceral Surgery for Advanced Gynaecological Malignancies. European Surgery 2003;35(2): 102–105.

[Weiss`77] Weiss N, Homunchuk T, Young JJ . Incidence of the histologic types of ovarian cancer: the third National Cancer Survey. 1969-71. Gynecol Oncol 1977;5: 161-167.

[Weiss`78] Weiss N, Peterson A. Racial variation in the incidence of ovarian cancer in the United States. Am J Epidemiol 1978;107: 91-95.


[Seite innerhalb Literaturhinweis 117↓]

[West`97] West RJ, Zweig SF. Meta-analysis of chemotherapy regimens for ovarian carcinoma: a reassessment of cisplatin, cyclophosphamide and doxorubicin versus cisplatin and cyclophosphamide. Eur J Gynaecol Oncol 1997;18: 343-348.

[Whittemore`92] Whittemore AS, Harris R, Itnyre J et al Characteristics relating toovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Am J Epidemiol 1992;136: 1184-1203.

[Wittekind`01] Wittekind Ch et al (eds) (International Union Against Cancer [UICC]) TNM supplement: a commentary on uniform use. (2nd edition) Geneva, Wiley-Liss 2001.

[Williams`01] Williams CJ. Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst Rev. 2001 ;(1): CD001034.

[Wimalasena`91] Wimalasena J, Neehan D, Cavallo C. Human epithelial ovarian cancer cell steroid secretion and its control by gonadotropins. Gynecologic Oncology 1991;41: 56-63.

[Wong Te Fong`01] Wong Te Fong LF, Siddiqui GK, Rolfe KJ et al Angiogenesis in primary epithelial ovarian carzinomas. Br. J. Obstet Gynaecology 2001;108: 555.

[Wong`03] Wong C, Wellman TL, Lounsbury KM. VEGF and HIF-1alpha expression are increased in advanced stages of epithelial ovarian cancer. Gynecol Oncol. 2003 Dec;91(3): 513-517.

[Wu`86] Wu PC, Qu JY, Lang JH. Lymph node metastasis of ovarian cancer: a preliminary survey of 74 cases of lymphadenectomy. American Journal of Obstetrics and Gynecology 1986;155: 1103–1108.

[Wu`89] Wu PC, Lang JH, Huang RL, Qu JY, Wang H, Tang MY et al Lymph node metastasis and retroperitoneal lymphadenectomy in ovarian cancer. Baillieres Clin Obstet Gynaecol 1989 Mar;3(1): 143-155.

[Yancik`86] Yancik R, Gloeckler RL, Yates JW. Ovarian cancer in the elderly: an analysis of surveillance, epidemiology, and end results program data. Amer J Obstet Gyn 1986;154: 639.

[Yeh`98] Yeh KH, Chen YC, Yeh SH, Chen CP, Lin JT, Cheng AL Detection of circulating cancer cells by nested reverse transcription-polymerase chain reaction of cytokeratin- (K19)--possible clinical significance in advanced gastric cancer. Anticancer Res. 1998 Mar-Apr;18(2B): 1283-1286.

[Yokoyama`03] Yokoyama Y, Charnock-Jones DS, Licence D et al Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma. Br J Cancer. 2003 Jan 27;88(2): 237-244.

[Young`03] Young RH. Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a gynecologic oncology group study. J Clin Oncol. 2003 Dec 1;21(23): 4350-4355.

[Young`94] Young RH, Scully RE. Sex cord-stromal, steroid cell and other ovarian tumors with endocrine, paraendorine, and neoplastic manifestations. In: Kurmann RJ ed. Blaustein. Pathology of the Female Genital Tract. Springer 1994:783-847.

[Zang`02] Zang R, Zhang Z, Cai S. Clinical significance of secondary cytoreductive surgery for recurrent advanced ovarian cancer. Zhonghua-Zhong-Liu-Za-Zhi. 2002 Mar;24(2): 194-196.

[Zeimet`98] Zeimet A G et al Ascitic Interleucin-12 is an independent prognostic factor in ovarian cancer. Journal of Clinical Oncology 1998;16(5): 1861-1868.

[Zhang`04] Zhang Y, Coogan PF, Palmer JR, Strom BL, Rosenberg L. Cigarette smoking and increased risk of mucinous epithelial ovarian cancer. Am J Epidemiol. 2004 Jan 15;159(2): 133-139.

[Zheng`00] Zheng W, Lu JJ, Luo F, Zheng Y, Feng Y, Felix JC, Lauchlan SC, Pike MC. Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone. Gynecol Oncol. 2000 Jan;76(1): 80-88.


[Seite innerhalb Literaturhinweis 118↓]

[Zhong`98] Zhong XY, Kaul S, Eichler A, Bastert G: Low Specificity of MUC1 as a Marker to Detect Epithelial Cancer Dissemination in Human Bone Marrow and Blood. Clin. Lab. 1998;44: 971-978.


© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
XDiML DTD Version 4.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am:
16.06.2005